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Obesity has detrimental effects beyond wellbeing, increasing susceptibility to 
metabolic and cardiovascular diseases. Multiple factors like, genetics, calorie-dense 
foods, physical activity and social environment contribute to its development. In the last 
decades, epidemiological and clinical research has revealed associations between 
perinatal events and propensity to develop obesity in adult life.  In particular intrauterine 
growth retardation (IUGR) has been associated with young and adult obesity and 
metabolic diseases.  The IUGR condition induces accelerated growth, hyperphagia and 
obesity in rodents offered high caloric diets after birth.  It has been discovered that 
hypothalamic regulation of energy homeostasis is defective in these animals due to an 
abnormal leptin profile during the first 2 postnatal weeks.  During this period, leptin 
stimulates the development of axonal projections between various hypothalamic centers.  
However, the ontogeny of this phenomenon is different between altricial rodents and 
precocial species such as humans and sheep.  Therefore, we used sheep to study the 
effects of the IUGR condition and high fat diets on immediate postnatal energy 
metabolism.  We confirmed that IUGR and normal lambs display similar intake relative to 
their metabolic size, however, they accrete excess fat when compared on similar body 
weight.  Our observations indicate that interactions between birth size and diet alter 
energy expenditure and retention through changes in thyroid hormones.  Second, we 
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evaluated the functionality of the melanocortin system, the best known mechanism of 
central control of energy intake and expenditure, and its effects on IUGR lambs.  Using a 
melanocortin receptor agonist, we confirmed that this system is functional as early as 
postnatal day 4 in IUGR and its stimulation reduces adiposity by decreasing appetite and, 
presumably, increasing energy expenditure.  Finally, we examined the role of leptin 
signaling during early life in the control of energy homeostasis and programming of 
future metabolic alterations and obesity.  We discovered that treatment with a long-
lasting leptin antagonist during the first two weeks of life acutely increases appetite and 
growth but has no long-term effects on appetite, growth or body composition. 
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CHAPTER  1 :  INTRODUCTION 
 
Through evolution, animals have regulated their energy reserves to successfully 
cope with the uncertainty of food availability, and simultaneously preserve body fitness 
to thrive within their ecological niche.  Consequently, the control of fat reserves is tightly 
regulated and involves biological mechanisms that regulate the two determinants of 
overall energy balance, namely energy intake and expenditure (1).  With more than 500 
million individuals suffering from obesity in the world, it is evident that these mechanisms 
frequently fail in humans (2).  In the U.S.A. alone more than 35% of the adult population 
is obese and an additional 33% presents some degree of overweight (3).  Beyond the 
evident detrimental effects on human wellbeing, obesity increases susceptibility to non-
communicable diseases like dyslipidemia, hypertension, type 2 diabetes and hepatic 
damage and is also associated with higher mortality rates (4). 
Scientists have shown that factors promoting obesity include genetics, greater 
availability of calorie-dense foods, lower physical activity and even the social 
environment (1, 5, 6).  In the last 4 decades however, evidence has accumulated for an 
additional factor contributing to the development of adult obesity and metabolic diseases.  
Specifically, Dorner, in Germany, and Barker, in England, suggested that nutrition during 
pregnancy has a major role in increasing the propensity of the offspring to develop 
diabetes or obesity during adult life (7, 8).  Since then, multiple epidemiological studies 
and clinical studies have supported their hypothesis that perinatal events can have long 
lasting effects leading to the promotion of excessive fatness (9–13).  This phenomenon 
is commonly referred as fetal or perinatal programming (14). 
2 
 
Among the different obesity programming paradigms, the intra-uterine growth 
retardation (IUGR) condition has generated interest due to its relevance to human 
populations (15).  Experiments with rodents have shown that the IUGR condition is 
associated with higher growth rates, higher appetite, lower locomotor activity, higher 
fatness and the incapacity to regulate caloric intake when offered calorie-dense foods 
(16–19).   
In parallel, remarkable advances have occurred in our understanding of the 
central control of energy intake and its interactions with the environment.  It is now well 
accepted that the central system regulates intake and energy expenditure through the 
integration of peripheral cues and signals of nutritional and environmental origin (20, 21).  
Interestingly, rodent models have shown that the IUGR condition is linked to a defective 
development of hypothalamic circuits responsible for the control of energy homeostasis 
(22, 23).  One current limitation in this field is near total reliance on rodent models.  
Rodents are altricial animals and appear to undergo key developmental events in a 
different window of life than the precocial human infant (24).  Most importantly, final 
development of the hypothalamus, the brain structure most involved in energy 
homeostasis, occurs during the first two postnatal weeks in rodents whereas it is mostly 
completed at birth in humans and other precocial animals (25–28).  Therefore, rodent 
models may not be ideal to study the programming of central regulatory mechanisms by 
the IUGR condition. 
 The pregnant sheep has long been viewed as an adequate model to study the 
progression and physiology of pregnancy (29).  Some of the advantages of this large 
animal model include relatively short gestation period, mother:fetus weight ratio similar 
to humans and the possibility of surgical intervention in both, mother and fetus (29).  
Because of these reasons and their precocial nature, they offer the possibility of more 
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accurately duplicating the events occurring in humans. In this dissertation a naturally 
occurring sheep IUGR model was used.  This model relies on inadequate placental 
mass during the last third of gestation to induce low birth weight.  Previous work has 
already described the propensity of these IUGR lambs to develop accelerated growth 
and higher adiposity by presumably increasing intake and reducing energy expenditure 
during early life (30).  However, multiple questions remain unanswered in this animal 
model.  
High-fat diets during the post-weaning period exacerbate the hyperphagia of 
IUGR rodents (18).  Would IUGR lambs be affected similarly if offered a high caloric diet 
during the accelerated growth period in early life?  What effects would this diet have on 
energy homeostasis and body composition?  
Also, it is known that both, energy intake and expenditure are regulated by the 
central system in response mainly to a peripheral hormonal cue called leptin that reflects 
the status of energetic reserves in the body (31).  This central modulation is mediated 
through a well-known system that involves peptides known as melanocortins and their 
receptors (20).  Given the immature state of IUGR lambs, is this system defective at birth 
in these animals?  Does the melanocortin system effectively regulate energy 
homeostasis and body composition during early life? 
Finally, as mentioned before, the development of hypothalamic centers 
responsible for energy homeostasis takes place during the first two weeks of life in 
rodents and leptin seems to be essential to this process (32).  Does leptin has the same 
neurotrophic role during early life in precocial species like sheep?  Would a defective 
leptin signaling induce a permanent alteration in energy homeostasis of these animals?  
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The overall objective of this body of research is to explore the role of IUGR and 
dietary fatness in the ontogeny of obesity in a species that more closely resembles the 
developmental stages of humans.  We focused on the functionality of the leptin-
melanocortin system responsible for the control of voluntary intake and energy 
expenditure. 
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CHAPTER  2 :  LITERATURE REVIEW 
The obesity epidemic in the human population 
Extent of problem.  Excessive adiposity or obesity is a growing concern in the 
world.  It is a considered a disease with clear etiology, signs and symptoms that affect 
not only the health but also the social and economic wellbeing of affected individuals (1, 
2).  Obesity has also been associated with increased morbidity of non-communicable 
diseases like dyslipidemia, hypertension, type-2 diabetes and hepatic damage (3).  
The need for a consistent way to assess adiposity resulted in the adoption of the 
body mass index (BMI).  BMI is defined as body weight divided by the square of height 
(4).  The World Health Organization has accepted BMI as an indirect measure of fatness 
in the general population.  In most world regions, the normal BMI range is 18 to 25 kg/m2 
(5).  A BMI falling between 25 and 29.9 kg/m2 indicates overweight whereas a BMI in 
excess of 30 kg/m2 indicates obesity (5).  Supporting the association between obesity 
and non-communicable diseases, any increment in BMI above 21 kg/m2 raises the risk 
to develop ischemic heart disease, stroke, hypertensive heart disease, diabetes, 
osteoarthritis, breathlessness, back pain, dermatitis, menstrual disorders and infertility, 
gallstones, as well as different types of cancer (6).  It is important to emphasize that 
although BMI has been an effective tool to describe the prevalence of obesity in a 
population, it is regarded as a poor predictor of overall fatness at the individual level.  
Piers et al. (7) demonstrated that the BMI is a poor predictor of the actual body fat 
content and has poor sensitivity.  Some researchers have suggested that other indexes 
such as waist circumference provide a better estimation of adiposity, especially for the 
visceral fat depot (8).  
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Many developed and developing societies face a serious threat to future 
wellbeing, health and productivity due to increased obesity rates (5).  In the US, 33% of 
the adult population suffer some degree of overweight (BMI between 25 and 30 kg/m2) 
and an additional 35% is obese (BMI>30 kg/m2) (3).  Worldwide the situation is not 
better:  in 2005, 23% of the world’s population was overweight and 9.8% was obese (9).  
Moreover, the BMI is still increasing in many parts of the world:  these increments 
average 0.4 units per decade for men and 0.5 units for women (calculated from 1980 to 
2008) (5).  
Causes of obesity.  In the most basic sense, excessive adiposity is the result 
of a positive imbalance between energy intake and energy expenditure.  Greater 
availability of calorie-dense foods, reduced physical activity and the social environment 
promote and facilitate this imbalance, increasing fat storage and obesity (10).  Evidence 
for a major environmental component for obesity is provided by significant increases in 
BMI for population as diverse as Pima Indians, Africans or Asians when living in 
developed countries such as the U.S. and U.K. (11, 12).  In addition, studies of 
monozygotic and heterozygotic twins have provided evidence of the remarkable genetic 
component of obesity.  Researchers have estimated that the heritability of BMI ranges 
between 0.50 and 0.70 (13, 14), and is second only to the heritability of height among 
physical traits (15). 
An additional factor that has received attention in recent years is the intrauterine 
environment (16, 17).  Over the last four decades, epidemiological studies have found 
significant correlations between various fetal events and the susceptibility to develop 
non-communicable diseases in postnatal life, including obesity and insulin resistance 
(18).  David Barker’s group (19) elaborated on these associations to develop the ‘thrifty 
phenotype’ hypothesis.  This hypothesis posits the existence of developmental plasticity 
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during prenatal life whereby the fetus engages metabolic adaptations to face adverse in 
utero conditions.  If irreversible, however, these adaptations become detrimental when 
postnatal conditions are normal.  For example, fetal undernutrition has been associated 
with insulin resistance in 8-year old infants and 50-year old adults (20, 21).  Phillips (22) 
suggested that this insulin resistance was the consequence of fetal adaptations that 
insured adequate glucose supply to the brain in uterine life but became unfitting after 
birth. 
 
Perinatal insults linked to excessive fatness in postnatal life 
Programming of future obesity and metabolic disorders has been associated with 
both, maternal over- or under-nutrition (23).  Several epidemiological studies have 
supported the association between maternal high BMI during gestation to higher birth 
weight and to the later development of obesity and metabolic syndrome in the offspring 
(24, 25).  The postnatal environment contributes to the higher adiposity in offspring but 
does not explain all of it.  For example, Dorner et al. (26) studied Germans born during 
and soon after World War II: diabetes was higher in individuals whose mother was well-
fed during pregnancy than those born from underfed mothers.  Also Dabelea et al. (27) 
analyzed pairs of siblings born before and after their mother developed diabetes mellitus. 
They found that children born after the onset of maternal diabetes were 3.7 times more 
likely to develop diabetes than siblings born before. 
At the other side of the spectrum, low birth weight has been linked to obesity and 
metabolic abnormalities in adulthood as well. Barker and colleagues (28) showed that 
women born to mothers exposed to the Dutch famine of 1944-1945 during the first third 
of gestation had higher BMI at age 50 than those born from non-exposed mothers.  Also, 
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a retrospective study of 64-72 year old white men indicated that low birth weight was 
associated with higher fat mass and fat percent as well as lower fat-free soft tissue and 
muscle mass than individuals of high birth weight (29).  Another study comparing elderly 
adults (55-73 years of age) monozygotic and dizygotic twin pairs discovered negative 
associations between birth weight on one hand, and fasting plasma glucose, fasting 
plasma insulin and insulin resistance index on the other, indicating a defective glucose 
metabolism in IUGR individuals (30).   
Gluckman et al. (31) made an important observation with regard to associations 
between the IUGR condition and non-communicable diseases.  They remarked that 
many studies that associate birth size with chronic diseases offer no indication of the 
effect that fetal adaptations may have in early post-natal life.  Their observation is 
relevant in the sense that most of the detrimental consequences of pre-natal growth 
retardation are known to relate to accelerated growth soon after birth (also known as 
catch-up growth) (32–34).   Studies conducted in different populations indicate a strong 
association between catch-up growth during the first months of life and higher BMI and 
adiposity of pre-adolescent children (35–37).  In addition, some researchers have made 
observations about the possibility of a metabolic programming window during the early 
postnatal period.  For example, Stettler et al. (38) determined that high milk replacer 
consumption during the first 8 days of life is positively associated with BMI of young 
adults (20 to 32 years old).  Also, Plagemann et al. (39) indicated that consumption of 
breast-milk from diabetic mothers during the first 7 days of life is positively correlated 
with body weight at 2 years of age.  
The present dissertation uses a multifoetal sheep model to explore the 
consequences of the IUGR condition on appetite and energy metabolism.  Accordingly 
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the review will focus on the biology of IUGR models in both rodents and sheep and their 
long-term effects on systems responsible for postnatal energy homeostasis.  
 
IUGR models and postnatal consequences on energy metabolism 
Results from research in rodent and large animal models support associations 
between the IUGR condition, and aberrations in postnatal energy metabolism and 
increased susceptibility to metabolic diseases.  In the early 70’s, Widdowson and 
McCance (40, 41) recognized that undernutrition during prenatal life or during early 
postnatal life can permanently alter growth trajectories and decrease mature size.  The 
following section will describe commonly used rodent and sheep IUGR models.  
 
Rodent models of IUGR 
 One simple method to induce prenatal growth retardation is to restrict maternal 
feed intake during gestation.  Desai et al. (42) restricted pregnant rats to 50% of ad 
libitum fed controls from gestation day 10 (G10) to term, inducing a mild reduction of 15% 
in birth weight.  These IUGR pups had higher growth rates and even surpassed the body 
weight of control animals at weaning on postnatal day 21 (P21) when crossfostered by 
ad libitum fed dams.  This difference in body weight persisted and was amplified by 36 
weeks of age.  This model may not be completely repeatable because a similar 
experimental design failed to generate differences in adult weight between IUGR and 
Control rats at P160 (43).  A greater degree of maternal nutritional limitations can induce 
permanent stunting in the offspring.  For example, Vickers et al. (44) imposed a 70% 
nutritional restriction to pregnant dams throughout pregnancy and observed a 39% 
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reduction in birth weight.  These offspring were never able to recover from the severe 
IUGR and were 85% of normal weight at P125.  
Both, the mild and severe prenatal undernutrition models described above have 
detrimental effects on postnatal energy metabolism.  In the milder model of feed 
restriction, IUGR offspring developed a higher absolute dry matter intake during the 
post-weaning period, but only if cross-fostered to mothers that were unrestricted during 
pregnancy and lactation (42).  However, this difference between IUGR rats and controls 
disappeared when intake was normalized to body weight (42).  In the extreme model of 
Vickers et al. (44), male IUGR rats developed higher relative caloric consumption than 
control animals before and after puberty, as well as during adulthood.  This difference 
was exacerbated when IUGR rats were fed a hypercaloric diet containing 55% of 
calories as fat (44).  In both models, hyperphagia of IUGR animals was associated with 
increases in adiposity: the mild model induced an increase of 83% in total body fatness 
at 9 months of age (42) whereas the more severe prenatal model induced a 10% 
increase in retroperitoneal fatness at P125 when rats were offered a normal diet (44).  A 
very important observation is that IUGR pups did not develop an adverse phenotype 
when their mothers were restricted during the lactation period (42).  Thus, a mismatch 
between fetal and postnatal nutrition exacerbates the effects of the IUGR condition.  
IUGR can even affect energy expenditure by reducing physical activity.  Vickers et al. 
(45) demonstrated that IUGR rats had lower locomotor activity at P35, P145 and P420, 
independently of the post-weaning dietary conditions.  
Another popular method to induce IUGR in rats involve the use of low protein 
diets (8-10% instead of 20%) throughout gestation (46–49).  Berends et al. (49) found 
that offspring of pregnant rats fed a low-protein diet were ~17% lighter at P3 and remain 
lighter until P7.  However, when cross-fostered onto dams fed a normal diet, male pups 
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became numerically heavier than normal pups at P110.  Surprisingly, these animals 
were not fatter than control rats at this age.  It is important to point out that other 
laboratories have failed to see higher body weight in this IUGR model at 4 months or 10 
months of age (50, 51).  This difference is probably the consequence of slightly different 
post-natal diets.  Low protein diets are also effective in inducing the IUGR condition in 
mice (52, 53).  Similarly to rats, IUGR mice developed higher rates of gain and adiposity 
when cross-fostered onto normally fed dams and offered highly palatable diets (52, 53).  
IUGR male mice and rats arising from this model have a 25% shorter lifespan when they 
are allowed to express accelerated growth before weaning (46, 48). 
It is not surprising that IUGR rodents that develop obesity also show defects in 
glucose metabolism and insulin action (54–56).  IUGR arising from sever maternal 
undernutrition had elevated circulating insulin concentration and hepatic glycogen 
content at P250 (54). Also, leptin levels in these animals are disproportionately higher 
than expected from their fatness at 9 months of age (55).  At the same age, IUGR 
arising from the milder model of maternal restriction and offered unrestricted postnatal 
nutrition suffered increased plasma glucose and insulin (56).  IUGR offspring from dams 
fed a low-protein diet during gestation and lactation show a better glucose tolerance at 3 
months of age with normal insulin levels (49).  However, by 15-mo of age, IUGR rats 
become even more glucose intolerant relative to control animals, presumably due to 
lower insulin sensitivity in males and lower insulin secretion in females (46).  
 
Sheep models of IUGR 
Sheep models have been extensively used in the study of maternal-fetal 
interactions (57).  Sheep models offer many advantages including the feasibility of 
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catheterization and frequent sampling of both, fetus and dam, under non-anesthetized 
and stress-free conditions (58, 59).  Additionally, it is one of the few precocial models 
used in biomedical sciences. The advanced degree of development of the neonatal lamb 
makes this species more comparable to infants than rodent models.  These 
characteristics and the renewed interest in the prenatal environment and its post-natal 
consequences have prompted the use of sheep models to study the IUGR condition. 
Several experimental manipulations have been used to induce IUGR in the 
sheep.  They include maternal heat stress, carunclectomy, large litters, overnutrition of 
adolescent ewes and nutrient restriction (60–63). A common feature of all these models 
is the significant reduction in placental mass or its nutrient transfer capacity.  The small 
placenta becomes unable to provide adequate nutrition to the fetus.  This limitation is 
most obvious over the last third of gestation when most of fetal growth occurs (64, 65).  
Exposure of pregnant ewes to a high temperature regime (40°C 9h/d, 30°C 15 
h/d, 40% rel. hum.) during the middle and/or final third of gestation can induce a 24-50% 
reduction in the weight of the offspring (66, 67).  For example, Alexander and Williams 
(66) demonstrated that placental weight is reduced ~67% by chronic heat stress of 
pregnant ewes during the last two thirds of gestation.  This placental weight reduction 
was associated with a 50% reduction in the birth weight of lambs.  They also 
demonstrated that placental size is restricted by 34% or 44% when heat stress is applied 
exclusively during the second or last third of gestation, respectively.  In both of these 
cases, size at birth is reduced by 30% (66).  In another study, Bell et al. (67) induced 
heat stress in pregnant ewes from day 64 to 136-141 of pregnancy, causing a 43% 
reduction in placentome weight, and a 17% reduction in fetal weight at day 141.  
Regnault et al. (68) initiated heat stress at day 37 of gestation and measured a 27% 
stunting of fetal weight by P93. 
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Another method consists on the surgical removal of the maternal site of placental 
attachment in the uterus prior to mating (69). These structures are known as caruncles.  
Carunclectomy can induce a ~35% reduction in fetal weight, but is also frequently 
ineffective due to compensatory placental adaptations (69–71).  Alexander (69) 
performed a series of experiments in which he removed up to 84 caruncles.  Birth size 
was negatively correlated with the number of caruncles removed, and even more closely 
related to the number and weight of the fetal portion of the placentome (also known as 
cotyledons).  Moreover, the weight of individual cotyledons was inversely related to the 
number of caruncles removed.  These observations suggested the existence of 
compensatory mechanisms to preserve placental capacity. 
Multifoetal pregnancies give rise to naturally occurring IUGR animals.  In the 
1980’s, two studies described the effects that ovulation rates, fetal number and uterine 
distribution of fetuses have on fetal growth of sheep (72, 73).  IUGR occurs frequently 
during multifoetal pregnancies because the fixed number of caruncles in the female 
uterus (80 to 100) and the uneven distribution of fetuses in the uterine horns impose a 
limit on placental development.  For example, the usual number of placentomes ranges 
from 27 to 73 for a singleton but is reduced to 8 to 32 for each fetus of a litter of 5 (72).  
The birth weight of individual lambs from multifoetal pregnancies is not only lower than 
that of singletons, but also more variable (73).  
Finally, maternal nutrient restriction can be an effective method to induce IUGR 
in the sheep (74, 75).  A 20-40% nutrient restriction throughout gestation induces a 40% 
reduction in fetal growth rate during the last third of gestation (74).  A 50% restriction in 
ME intake during the last third of gestation induced a 22% reduction in birth size (76).  
However, when the same restriction is limited to days 30 to 80 of a 148-day gestation, it 
does not alter birth weight (77).  Paradoxically, maternal overnutrition also leads to the 
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IUGR condition naturally if applied to adolescent ewes (78).  In this model, adolescent 
ewes are fed twice the normal maintenance energy requirement during the entire 
gestation period.  Overnutrition induces maternal growth and obesity, a 45% reduction in 
placental mass and a 28-38% reduction in the weight of the neonate (78). The 
mechanistic basis for this effects appears to be a re-direction of nutrients towards 
maternal growth at the expense of placental and fetal tissues (62).  Overnutrition limited 
to early gestation does not induce IUGR because it does not limit placental growth 
during the second third of gestation.  This suggests that, in adolescent ewes, placental 
and fetal tissues are most sensitive to overnutrition during the last two thirds of gestation.  
Effect on postnatal appetite.  A unique advantage of ovine models is the 
feasibility of measuring voluntary feed intake before weaning (63).  Lambs can be 
separated from the mother at birth and transferred to a controlled-environment facility 
where they are fed a milk replacer.  Using this system, Greenwood et al. (63) evaluated 
growth, intake, development and metabolism of Normal and IUGR lambs arising from 
the naturally occurring multifoetal model.  Lambs were either fed ad libitum or restricted 
to grow at a rate of 150 g/day.  In their experiment, IUGR lambs were 52% smaller at 
birth (2.3 vs. 4.8 kg) and presented signs of altered appetite during early life.  Relative 
intake was higher in IUGR for around 20 days after birth, with a maximum difference of 
around 20% reached during the first or second week of life, depending on the plane of 
nutrition.  Interestingly, when relative intake was compared at equal weight, IUGR and 
Normal lambs did not differ.  In other words, IUGR had a higher relative feed intake only 
until they reached the birth weight of Normal lambs.   
De Blasio et al. (79) studied IUGR neonates arising from the carunclectomy 
model.  These lambs suffered a 25% reduction in birth weight (4.15 vs. 5.53 kg).  Lambs 
were reared naturally and no measurements of intake were obtained in these animals.  
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However, at day 15 of life, the number of suckling events, total suckling time and 
average suckling time were recorded for 1.5 h after a 1-h fast.  None of the parameters 
differed between IUGR and Normal lambs.  Nevertheless, the authors suggested that 
IUGR exhibited an altered pattern of suckling that correlates with higher growth rates 
and adiposity.  
Effect on postnatal growth and adiposity.  Given a lower weight at birth, 
IUGR lambs typically have lower absolute rates of gain than normal-birthweight lambs 
(63).  On the other hand, IUGR lambs consistently achieve higher fractional weight gain 
(i.e. gain normalized to body weight) than Normal lambs for the first 4 to 8 weeks of life 
(61, 63, 80).  Interestingly, just as observed with relative feed intake, the fractional 
weight gain of IUGR lambs does not differ from Normal lambs when compared at the 
same body weight. 
Just as observed in humans, the IUGR condition in sheep is associated with 
higher total adiposity later in life (61, 63, 80, 81).  For example, Greenwood et al. (63) 
observed higher levels of total body fatness in IUGR than Normal lambs at any body 
weight up to 20 kg.  This was true for lambs offered unlimited amounts of milk replacer 
or restricted to grow at the fixed rate of 150 g/day.  Loey et al. studied female IUGR that 
were 38% lighter than controls at birth as a result of placental embolization (80).  When 
studied at 2-3 years of age, they had 27% higher total fat mass and 39% higher 
abdominal adiposity.  Finally, when naturally reared, IUGR lambs resulting from 
carunclectomy had higher relative mass of perirenal (0.8 vs. 0.5% of BW), omental (1.0 
vs. 0.8% of BW) and total visceral fat depots (2.3 vs. 1.5% of BW) than normal weight 
lambs at day 43 of age (61, 81). 
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Effect on glucose metabolism.  As mentioned above the sheep offers the 
feasibility of repeated blood sampling in both fetus and dam.  Data on glucose and 
insulin in fetal sheep illustrate adaptations induced by the IUGR condition.  Placental 
insufficiency induces a reduction in uterine and umbilical blood flow along with lower 
glucose and oxygen delivery to the fetus (78, 82).  Surprisingly, despite having lower 
relative glucose uptake, IUGR fetuses have similar weight-specific glucose utilization 
rates as Normal fetuses, indicating an increase in endogenous glucose production (82).  
In line with this observation, the expression of phosphoenolpyruvate carboxykinase and 
glucose 6 phosphatase mRNA is increased in liver of IUGR lambs (83).  Under basal 
conditions or during a glucose clamp, glucose utilization in IUGR fetuses is almost 
identical to controls, despite a significant ~70% reduction in plasma insulin concentration 
(82).  Using the mid-gestation heat-stress model, Limesand et al. (84) reported that 
pancreatic islets of the IUGR fetus have lower insulin biosynthesis than control fetuses.  
They also found that β-cell mass is decreased in severe cases of IUGR as a result of 
longer cell cycle and lower mitosis rate (85).  These data are consistent with major 
metabolic adaptations in IUGR lambs during fetal life.  
Hypoglycemia and hypoinsulinemia are often observed at birth in the different 
IUGR models (62, 83, 86, 87) and are seen as an extension of the prenatal condition.  
De Blasio et al. (81) studied glucose metabolism in IUGR lambs arising from the 
carunclectomy model at 1 month of age.  By the hyperinsulinemic-euglycemic clamp, 
they determined that insulin sensitivity with respect to glucose metabolism was not 
different between control and IUGR lambs when studied at 1 month of life (81).  
However, they determined that the ability of insulin to decrease circulating free fatty 
acids was greater in IUGR lambs, and argued that this adaptation contributed to the 
increased visceral adiposity of these lambs.  On the other hand, Husted et al. (88) 
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performed glucose tolerance tests at 10 and 19 weeks of age on control and IUGR 
lambs born to feed-restricted ewes.  Glucose tolerance was not altered at any time in 
IUGR animals but they had higher glucose-stimulated insulin secretion at 19 weeks of 
age.  It is important to mention that in both studies, IUGR lambs were at least 10% 
smaller than Normal lambs when these studies were performed. 
Effect on metabolic hormones.  It is known that the growth hormone/insulin-
like growth factor-1 (GH/IGF-1 system) partially mediates the effect of nutrition on growth 
in the young ruminant (89).  This important growth system is also sensitive to nutrition 
during prenatal life.  Circulating GH concentration is elevated in IUGR fetuses of ewes 
restricted during the last third of pregnancy or subjected to a 48 h starvation period 
between day 120-130 of gestation (90, 91).  In response to a low maternal plane of 
nutrition, IUGR fetuses present low circulating IGF-1 during the last third of gestation 
(92).  During this period, plasma IGF-1 is positively associated with fetal weight, fetal 
liver weight, blood pO2 and circulating glucose.  In fact, although fetal IGF-1 plasma 
concentration is relatively low during gestation, it can rapidly respond to starvation and 
fluctuations in circulating glucose during the last 10 days of gestation (93).  Along the 
same line, Rhoads et al. (94) reported that hepatic expression of IGF-1 and the acid-
labile subunit (ALS) is reduced in IUGR fetuses as early as day 130 day of gestation.   
After birth, IUGR lambs continue to have a higher plasma concentrations of GH 
than Normal lambs (49.1 vs. 10.8 μg/l) for the first two weeks of life (95).  Circulating 
IGF-1 remained significantly lower at birth (36 vs. 158 μg/l) but becomes responsive to 
postnatal plane of nutrition during the first week of life, independently of birth weight (95).  
IGF-1 concentration rose and reached a maximum before 13 days of life in IUGR and 
normal lambs fed ad libitum but concentrations remained lower in IUGR animals (95).  
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When neonatal lambs were feed restricted to gain only 150 g/d, however, plasma IGF-1 
concentration was consistently low in both, IUGR than Normal lambs (95).  
IUGR lambs are in a hypothyroid state at birth (96), similar to their human 
counterparts (97, 98).  Cabello and Levieux (96) analyzed lambs ranging from 1.22 to 
3.55 kg born to prolific Romanov ewes and found positive correlations (>0.55) between 
birth weight and T3 and T4 status during the immediate postnatal life.  Furthermore, 
Cabello (99) found that IUGR neonatal lambs had a reduced ability to increase T4 
production during cold challenges, resulting in hypothermia and high mortality rates.  
Later Dwyer and Morgan (100) confirmed that the low T3 and T4 status of IUGR lambs 
is not only associated with poor thermogenic capacity, but also with poor behavioral 
progress to stand and suckle.  However, thyroid status of naturally reared IUGR and 
normal lambs is not related to their fractional growth rate (79). 
Using the multifoetal ovine model, Ehrhardt et al. (101) demonstrated that 
plasma leptin concentration in early life is not affected by birth weight and is better 
associated with lipid accretion rates than adiposity itself.  On the other hand, De Blasio 
et al. (102) found that leptin plasma concentration of IUGR lambs from carunclectomized 
ewes was higher than control lambs on day 5 of postnatal life but not different afterwards.  
Additionally, they suggested a negative relationship between leptin concentration and 
feeding activity (suckling events) on postnatal day 15 in Normal lambs and that the IUGR 
condition reversed this relationship.  They reached this conclusion even though suckling 
events did not differ between IUGR and Normal lambs (102). 
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Central control of energy homeostasis. 
Early evidence for involvement of the hypothalamus.  The role of 
hypothalamic centers in the control of energy homeostasis was first suggested by 
studies conducted during the 1940’s in which electrolytic lesions of specific regions of 
the rat hypothalamus induced hyperphagia and fatness (103).  Years later, a parabiosis 
experiment between rats with hypothalamic lesions and intact animals offered the first 
evidence of peripheral cues indicative of energy reserves acting on hypothalamic 
feeding center (104): hyperphagia and marked obesity occurred in the lesioned rat 
whereas the intact animal ate less and lost weight.  This suggested the presence of a 
circulating satiety factor emanating from the obese rat and acting in the intact rat to 
reduce intake and body weight.  During the 1950-1970 period, the identification of the ob 
and db mouse strains as well as parabiosis experiments with these mutant mice offered 
further evidence of a circulating factor acting through its cognate receptor to control 
appetite and metabolism (105, 106).  This model was finally confirmed in the 1990’s by 
the discovery that the ob gene encodes the protein leptin and that the db gene encodes 
its receptor (107, 108).  These studies also showed that leptin is expressed in proportion 
to fat mass and regulates appetite and energy expenditure by acting predominantly on 
the central nervous system (107).  The hypothalamus receives and integrates many 
other peripheral cues produced by adipose tissue and the gastrointestinal tract.  This 
integration allows for the coordinated control of energy and glucose homeostasis in the 
organism (109). 
Hypothalamic organization.  The hypothalamus consists of nuclei or groups 
of neurons sharing common functions (110).  A key hypothalamic nucleus is the arcuate 
nucleus (ARC).  It is located near the medium eminence where the blood-brain barrier is 
more permeable (111).  Most of its residing neurons express receptors for metabolites 
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and hormones (112).  Because of these properties, the ARC is believed to be an ideal 
center to read peripheral cues indicative of energy balance and adiposity such as leptin. 
The ARC contains 2 neuron-populations that are important for regulation of 
energy intake and energy expenditure (110).  The first population consists of NPY/AGRP 
neurons, based on their co-expression of two neuropeptides called neuropeptide Y (NPY) 
and agouti-related peptide (AGRP).  The NPY/AGRP neurons are considered orexigenic 
because intracerebroventricular (ICV) injection of these two neuropeptides induces 
significant increases in food intake and weight gain (113, 114).  The second group is 
known as POMC/CART neurons based on co-expression of pro-opiomelanocortin 
protein (POMC) and cocaine and amphetamine-related transcript (CART).  The 
POMC/CART neurons have anorexigenic properties because ICV injection of CART or 
α-melanocortin stimulating hormone (α-MSH), the proteolytic product of POMC, inhibit 
voluntary intake (115, 116). 
Genetically modified mouse models have provided further evidence about the 
reciprocal role of the NPY/AGRP and CART/POMC neurons.  Hypothalamic 
overexpression of NPY or AGRP in mice causes hyperphagia and obesity (117, 118).  
On the other hand, acute ablation of AGRP/NPY neurons in adult mice cause severe 
anorexia but has no effect if done in neonatal animals, perhaps due to developmental 
compensation by other pathways (119).  Interestingly, NPY null mice did not show 
alterations in appetite or body weight (120).  Null AGRP mice have a normal intake and 
energy expenditure when young but develop lower body weight and elevated metabolic 
rate by adulthood (121). Null POMC mice, on the other hand, show higher voluntary 
intake, higher fat accretion, lower circulating T4 and depressed metabolic rate (122). 
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ARC neurons are considered first-order or sensory neurons because they have 
an abundance of receptor for leptin, insulin and other peripheral cues (112).  In general, 
activation of these receptors has reciprocal effects on AGRP/NPY and CART/POMC 
neurons.  For example, leptin inhibits production and release of AGRP and NPY by 
orexigenic neurons whereas it increases production of POMC and CART by the 
anorexigenic neurons (123, 124).  Thus, when energy reserves are high, plasma leptin is 
elevated leading to increased POMC/CART and reduced AGRP and NPY production, 
inducing a reduction in voluntary feed (123, 124). 
However, ARC neurons are not directly responsible for functional outputs such 
as changes in feed intake and energy expenditure (125).  These functions are carried 
out by neurons located in other hypothalamic nuclei and brain centers.  These ‘second-
order’ nuclei include the paraventricular nucleus (PVN), ventromedial hypothalamus 
(VMH), dorsomedial nucleus (DMN), and perifornical and lateral hypothalamic areas 
(LHA) (126). ARC neurons are linked to these second order neurons via an extensive 
network of axonal projections.  They themselves project to other central nervous 
structures such as the dorsal vagal complex (DVC), which includes the nucleus tractus 
solitarius (NTS) and the dorsal motor nucleus of the vagus (DMV).   
 
The central leptin-melanocortin system 
Leptin is obviously not the only peripheral cue read by hypothalamic neurons 
(110).  Similarly, the melanocortins (MC) AGRP and POMC are not the only important 
neuropeptides regulating energy homeostasis (127).  Nevertheless, the following section 
will focus on leptin and the role of the central MC system in mediating its effect.  This will 
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be done because it is by far the better understood system involved in the energy 
homeostatic function of the central nervous system.  
Both, insulin and leptin circulate in proportion to body fat content and are sensed 
by receptors in the hypothalamus (110).  They are regarded as playing important roles in 
short- and long-term regulation of energy homeostasis.  In fact, ICV infusion of either 
hormone reduces voluntary intake in non-human primates and mice (128, 129).  
Although both, insulin and leptin circulate in proportion to adiposity, only a leptin 
deficiency causes hyperphagia and obesity, indicating the predominant importance of 
this hormone in the control of energy intake and expenditure (110).  Leptin actions are 
mediated via the functional long form of the leptin receptor (Ob-Rb) located on both, 
NPY/AGRP and POMC/CART neurons (130).  
As reviewed above, leptin increases POMC expression and production of its 
proteolytic product α-MSH and has the opposite effect on AGRP production. α-MSH and 
AGRP are known as melanocortins.  There are 5 known melanocortin receptors, but only 
melanocortin receptor 3 (MC3R) and 4 (MC4R) are found in the brain and prominently 
expressed in many second order neurons (131).  In terms of their actions on MC3R and 
MC4R, α-MSH and AGRP are functional opposites with α-MSH acting as an agonist and 
AGRP as an antagonist (132).  As a result, activity of central MC receptors is regulated 
by the ratio of α-MSH and AGRP (α-MSH/AGRP ratio) produced in the ARC. 
The importance of MC action via central melanocortin receptors is illustrated by 
the hyperphagia, hyperinsulinemia, hyperglycemia and obesity seen after total ablation 
of MC4R in the hypothalamus (133).  
The PVN and LHA are second order nuclei abundantly supplied with axonal 
projections from both, NPY/AGRP and POMC/CART neurons.  This has been shown in 
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both, rodents and non-rodent species, like sheep (134, 135).  Injections of AGRP directly 
into the PVN induce a significant increase in voluntary intake (136).  Also, re-expression 
of the MC4R only in the PVN was sufficient to correct the hyperphagia of MC4R 
knockout mice, but did not normalized their reduced energy expenditure (137).  Together, 
these experiments indicate that the MC α-MSH acts in the PVN to modulate feed intake 
but its effect on metabolic rate likely involves another nuclei.  Importantly, neurons within 
the PVN express corticotrophin-releasing hormone (CRH), thyrotropin-releasing 
hormone (TRH), oxytocin and vasopressin, integrating energy homeostasis with systems 
regulating glucocorticoid production, metabolic activity and fluid balance (126).  The LHA 
is another important second-order nucleus that also receives significant efferent axonal 
projections from the ARC.  This nucleus contains groups of neurons that express the 
additional orexigenic neuropeptides, orexins and melanin concentrating hormone (MCH) 
(126).  
Central melanocortin and regulation of energy expenditure.  In addition 
to effects on energy intake, the hypothalamus regulates energy expenditure via 
endocrine and autonomic pathways (138).  MC are partly responsible for the regulation 
of synthesis and secretion of TRH in neurons located in the PVN and, therefore, for the 
activity of the hypothalamic-pituitary-thyroid (HPT) axis (139).  Thyroid hormones are 
central modulators of both basal and induced thermogenesis.  In fact, both basal and 
cold-induced thermogenesis can be severely reduced in the absence of thyroid 
hormones (140).  The thermogenic effect of thyroid hormones involves uncoupling 
proteins not only in brown adipose tissue (BAT) (141) but also in muscle (142), where 
substrate flux to the TCA cycle is increased without increases in ATP production (143).  
When circulating leptin is low during fasting, the levels of thyroid hormones are reduced 
(144–146).  In contrast the systemic or central administration of leptin during fasting is 
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sufficient to normalize TRH expression in the PVN (139).  Legradi et al. (147) found that 
pharmacological ablation of the ARC eliminates not only the drop in TRH and TSH 
during fasting, but also the stimulatory effects of exogenous leptin treatment.  TRH 
neurons in the PVN have been shown to express MC3R and MC4R (148).  ICV 
administration of α-MSH in fasted animals restored the expression of TRH in the PVN 
while infusions of AGRP induced a state of hypothyroidism in ad libitum fed rats, similar 
to that observed in fasting animals (139).  These experiments support an important role 
for the melanocortin system in mediating effects of leptin and ARC neurons on TRH 
synthesis and therefore, thyroid hormone-dependent energy expenditure. 
The central melanocortin axis also regulates metabolic rate by stimulating the 
autonomic nervous system.  Experiments with rats conducted by Haynes et al. (149) 
demonstrated that leptin is capable of increasing significantly the activity of sympathetic 
nerves serving all tissues and organs (e.g. BAT, muscle, kidney and adrenal glands).  In 
order to determine if leptin effects on sympathetic activity were mediated by 
melanocortin receptors, Haynes et al. (149) used both, MC4R agonist and antagonist to 
evaluate regulation of sympathetic activity in brown adipose tissue.  They discovered 
that ICV infusion of a melanocortin receptor agonist induced a dose-dependent increase 
in sympatho-excitation of brown adipose tissue, kidney and hind limb (149).  Moreover, 
Brito et al. (150) demonstrated that central melanocortin administration induced lipolysis 
and increased temperature not only in BAT but also in some white fat depots.  In support 
for a role of central MC in the control of energy expenditure, MC4R knockouts have 
lower energy expenditure, lower oxygen consumption as well as an elevated respiratory 
exchange ratio indicative of reduced lipid oxidation (151). 
There are few data in sheep regarding regulation of energy expenditure by the 
leptin-central MC system.  A significant finding in this context was the observation that 
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central leptin administration increases thermogenesis in sheep (152).  This increase was 
associated with increased expression of UCP2 and UCP3 genes in muscle as well with 
increased uncoupled respiration in mitochondria isolated from muscle (152). 
Central melanocortin and modulation of metabolism.  In addition to the 
overall regulation of energy balance by modulating intake and metabolic rate, 
hypothalamic centers also contribute to glucose and lipid partitioning and utilization in 
peripheral tissues.  For example, chronic peripheral leptin therapy of ob/ob mice for five 
days reduces circulating insulin and glucose concentrations before obesity and 
hyperphagia are resolved (153).  Furthermore, these reductions are larger than those 
observed in pair-fed ob/ob controls, indicating that leptin has intake independent effects 
on glucose metabolism.  Later, Rossetti et al. (154) used hyperinsulinemic clamps to 
demonstrate that leptin enhances the ability of insulin to reduce hepatic glucose output.  
They also showed that leptin actions included intra-hepatic suppression of 
glycogenolysis and a stimulation of gluconeogenesis.  In support of the previous 
experiments, ICV or peripheral leptin infusions alone reduced hyperglycemia induced by 
chemical or autoimmune β-cell destruction (155, 156). 
The actions of leptin in the central control of glucose metabolism has been found 
to take place within the ARC (157).  Effects of leptin on hepatic glucose metabolism are 
seen even if leptin is administered only in the brain (158).  Despite the modest effects on 
intake and body weight, molecular restoration of leptin receptor expression exclusively in 
the ARC of db/db mice greatly improves hyperglycemia and hyperinsulinemia in these 
animals (157).  This indicates that a lack of leptin signaling in the ARC of db/db mouse 
plays an important, adiposity independent, role in glucose metabolism.  Furthermore, 
rescue of leptin receptors only in POMC/CART neurons solved the hyperglycemia and 
ameliorated hepatic insulin resistance, hyperglucagonemia, and dyslipidemia in leptin 
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receptor deficient mice (159).  Acute peripheral leptin infusion also induces a reduction 
in lipogenesis in liver and white adipose tissue in mice (160).  ICV leptin infusion in rats 
represses the expression of key lipogenic genes such as acetyl-coenzyme A-
carboxylase, fatty acid synthase and stearoyl-coenzyme A desaturase-1 (161). 
A significant portion of leptin effects on glucose and lipid metabolism is mediated 
by the MC receptor.  Fan et al. (162) demonstrated that a melancortin agonist inhibited 
basal insulin release by ob/ob mice in a dose dependent manner via the sympathetic 
nervous system.  Interestingly, glucose tolerance was also impaired during melanocortin 
treatment.  In order to dissect the effect of obesity and melanocortin receptor stimulation 
on glucose metabolism, the same group evaluated concentrations of circulating insulin 
as well as glucose tolerance in MC4R null mice.  At 4 weeks of age hyperglycemia and 
glucose intolerance were evident even before these mice became fatter than wild-type 
mice (162). 
Nogueiras et al. (163) explored the role of hypothalamic melanocortin signaling 
on lipid metabolism.  They demonstrated that pharmacological inhibition of MC4R 
induced greater body weight, feed efficiency, greater fat accretion and lower fat oxidation 
than pair-fed controls.  In line with this phenotype, expression of genes linked to lipid 
uptake and lipogenesis was increased in white adipose tissue of these animals.  
Reciprocally, they also showed that melancortin receptor activation reduced weight, feed 
efficiency and fat accretion to a greater extent than pair fed controls.  This was 
associated with higher adipose tissue expression of lipolytic genes such as hormone-
sensitive lipase and adipose-triglyceride lipase.  Their experiment also demonstrated the 
relevance of the sympathetic nervous system in mediating these effects.  During ICV 
treatment with a melanocortin agonist, sympathetic nervous activity in white adipose 
tissue increased in a dose dependent manner.  This increase was prevented by co-
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infusion of melanocortin agonist and antagonist.  Although these results only showed the 
direct autonomic connection between MC4R-neurons and white adipose tissue, an 
experiment in mice lacking all β-adrenergic receptors offered further insight: chronic ICV 
infusion of a melanocortin receptor antagonist did not increase body weight and failed to 
induce FAS expression (163).  These results confirmed the importance of β-adrenergic 
signaling in mediating the effects of central melanocortin on lipid metabolism.  Overall, 
this work demonstrates that the central nervous system modulates lipogenesis and lipid 
accretion in white adipose tissue via the sympathetic nervous system. 
 
The role of perinatal nutrition and leptin in regulating hypothalamic 
development 
As mentioned previously in this review, different hypothalamic nuclei are involved 
in the regulation of appetite (110).  The neurons populating these nuclei are 
interconnected via axonal and dendritic projections.  This network allows reception and 
integration of signals by the hypothalamus so that appropriate responses are mounted.  
Remarkably this network of axon connections develops at different stages of life in 
altricial and precocial animals (e.g. rats and mice vs. humans, non-human primates and 
sheep).  For example, ARC, DMH, VMH and LHA neurons can be detected in mice 
embryos as early as day 11 of fetal life (164). However, ARC axonal projections to 
second-order neurons located in the PVN, VMH and LHA are virtually absent at birth and 
are not fully developed until the end of the third week of age (165).  Because of this, 
leptin regulation of energy homeostasis is not present in early postnatal rodents.  For 
example, leptin treatment for 7 days did not induce changes in body weight in 10-day old 
mouse pups (165), whereas the same treatment is highly effective in adult mice. In 
31 
 
humans, non-human primates and sheep, ARC neurons can be identified during the 2nd 
trimester of fetal life (166–168). In stark contrast with rodents most axonal development 
between the ARC and the other hypothalamic nuclei occurs during the last third of 
gestation in these animals (167, 169).  
Several research groups have described a 5 to 10-fold increase in plasma leptin 
during the second week of life in rodents (170, 171).  Ahima et al. (170) observed that 
this increase in circulating leptin was not associated with adiposity, could not be 
prevented by feed restriction and did not induce a reduction in body weight. Other 
groups demonstrated that exogenous leptin was able to induce changes in POMC and 
NPY expression in the ARC of pre-weaned rodents but did not alter food intake or body 
weight (165, 172).  In pre-weaned rodents, leptin-dependent activation of second-order 
neurons was proportional to the density of efferent axonal projections received from the 
ARC (165).  Based on the timing of activation of hormonal systems regulated by the 
hypothalamus, Ahima et al. (170) suggested that leptin could have a neurotrophic role 
that allowed for adequate development of hypothalamic-pituitary-adrenal, gonadal and 
thyroid axis.  In agreement with this hypothesis, Bouret et al. (173) later demonstrated 
that leptin was essential for the proper development of the axonal network between the 
ARC and secondary hypothalamic nuclei involved in energy homeostasis.  They 
demonstrated that chronic leptin treatment from day 4 to 12 of postnatal life could rescue 
the poor density of such axonal projections in leptin deficient (ob/ob) mice.  Moreover, 
intake was somewhat normalized in these ob/ob mice on postnatal day 32 in absence of 
concurrent leptin administration.  Remarkably, leptin therapy was ineffective in restoring 
this neural network when it was administered to adult ob/ob mice.  This suggested that 
the developmental role of leptin is largely restricted to the early neonatal period, which 
coincides with a natural surge of circulating leptin (170).  
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As mentioned earlier in this review, the IUGR condition induces a hyperphagic 
and obese phenotype in postnatal rodents, particularly when they are offered high fat 
diets during the post-weaning period (56, 174). Delahaye et al. (175) showed that the 
IUGR condition induced by maternal undernutrition ablates the normally occurring surge 
of leptin in neonatal rats.  Also, Vickers et al. (174) tested whether exogenous leptin 
treatment during early life (P3 to P13) could correct the abnormal energy metabolism of 
IUGR rat pups.  This neonatal therapy completely normalized adult body weight, body 
weight gain, caloric intake, locomotor activity, fat mass, as well as fasting plasma insulin, 
glucose and leptin in IUGR rats.  Overall, these findings lead to a model whereby the 
IUGR condition leads to a neonatal leptin deficiency, followed by inadequate axonal 
development in the hypothalamus. Failure to complete this developmental event would 
then account for inappropriate energy metabolism later.  The applicability of such a 
model to precocial species that complete hypothalamic axonal development in late fetal 
life is unknown.  There is no evidence relative to the potential neurotrophic effect that 
leptin might have in the proper development of the leptin-MC system in precocial species 
or the time window when this could take place.  Also, it is unknown if the hyperphagic 
and fat phenotype observed in IUGR lambs during early life is the result of a defective 
central leptin-MC system as it is the case in rodents.   
Summary 
Epidemiological evidence indicate that the IUGR condition is associated with 
higher risk for obesity and metabolic disorders (28–30).  These observations are 
supported by clinical experiments with rodents in which the IUGR condition can induce 
hyperphagia and excess fatness, especially if these animals experience over nutrition or 
are fed high-caloric diets (42, 44).  This adverse phenotype is associated with poor 
development of hypothalamic networks involved in the control of energy intake and 
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expenditure.  It has been discovered that hypothalamic development of energy 
homeostasis is defective in these animals due to abnormal leptin profile during the first 2 
postnatal weeks.  Leptin has neurotrophic capacities exclusive to this period and is 
essential for the development of proper connectivity between hypothalamic centers.  
However, ontogenesis is different in altricial rodents compared to precocial humans, 
non-human primates and sheep.  This leaves unanswered questions.  1) Does higher 
energy diet exacerbate the negative effect of the IUGR condition when offered 
immediately after birth? 2) Is the central melanocortin system functional immediately 
after birth? 3) What is the role of leptin in the regulation of energy metabolism in the 
immediate postnatal period? and, 4) Does a lack of leptin signaling in early postnatal life 
have long-term consequences?  
Our multifoetal-model of IUGR and our artificial rearing system offers the 
opportunity to test the capacity of precocial animals to regulate intake of diets with 
different caloric density during early life.  Furthermore, we studied the impact that these 
diets have on body composition in interaction with the IUGR condition.  Also, the 
functionality of the melanocortin receptor has never been tested during early life in 
precocial species.  We were able to do this using a melanocortin agonist capable of 
crossing the blood-brain barrier.  Finally, to explore the role of leptin during early life in 
the short- and long-term control of energy homeostasis and body composition, we used 
a long-lasting leptin antagonist during the first weeks of life in sheep.  This novel series 
of experiments will offer important insight in the mechanisms regulating energy intake 
and expenditure in a relevant precocial animal model.  
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CHAPTER  3 :  EFFECT OF BIRTH SIZE AND DIETARY FAT ON INTAKE, 
GROWTH AND BODY COMPOSITION OF NEONATAL LAMBS 
 
Introduction 
A chronic positive imbalance between energy consumption and energy 
expenditure results in excessive adiposity.  Several factors like genetics, greater 
availability of caloric-dense foods, reduced physical activity and social environment have 
been implicated as promoters of this imbalance (1–3).  Excessive adiposity has 
developed into a medical and economic problem over the last decades.  Obesity is not 
only associated with an increased susceptibility to non-communicable diseases like 
dyslipidemia, hypertension, type 2 diabetes and hepatic damage but also with higher 
mortality rates (4, 5).  Based on the body mass index (BMI), over 65% of the population 
in the US is either overweight (BMI between 25 and 30 kg/m2) or obese (BMI>30 kg/m2) 
(5).  The situation is not better worldwide:  an extensive analysis of BMI indicates that it 
has increased globally since 1980 at the rate of 0.4 and 0.5 kg/m2 per decade in men 
and women, respectively (6).  
Obesity is also becoming an alarming condition of childhood and adolescence.  
Over 170 million children and adolescents are estimated to be overweight worldwide (7).  
In the US alone, obesity affects 12.5 million children and adolescents (8).  There is 
growing evidence in recent years that various fetal insults, including both under- and 
over-nutrition, contribute to the increased adult obesity and metabolic disorders of this 
cohort (9–12).  
Various rodent models have been used to explore how fetal insults lead to 
greater adiposity in adult life (13–15).  A common feature of many of these models is the 
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imposition of caloric or protein restriction to the dam, leading to fetal undernutrition and 
the birth of pups suffering from intrauterine growth retardation (IUGR).  Remarkably, 
these IUGR pups have an increased predisposition to develop obesity after weaning, 
particularly when offered a high fat (HF) diet (13–15).  
Rodent models, however, have two limitations.  First, it is technically difficult to 
manipulate the diet before weaning.  This relates to the absolute dependence of the 
newborn rodent on maternal milk for the first 2-3 weeks of life and the difficulty to alter 
milk composition.  Accordingly, the consequences of varying diet composition in early life 
on the abnormal energy metabolism of IUGR animals have not been well studied.  
Second, the central system responsible for appetite regulation is less developed in 
rodents than in human at birth (16–20).  Accordingly, it is unclear whether metabolic 
defects identified in pre-weaned IUGR rodents apply to their human counterpart.  The 
newborn sheep is an excellent model with respect to these two limitations.  Neonatal 
lambs can be fed artificially from birth and milk replacer composition can be easily 
manipulated (21).  Moreover, hypothalamic development at birth is comparable in sheep 
and primates (18, 19).  Greenwood and colleagues (21–24) described an IUGR sheep 
model characterized by increased appetite and reduced energy expenditure in early 
postnatal life.  Accordingly, our objective was to assess whether these and other 
features of the IUGR condition were exacerbated in this sheep model by increasing the 
energy density of the diet in the immediate postnatal period.  
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Materials and Methods 
Animals and study design.  All experimental procedures were approved by 
the Cornell University Institutional Animal Care and Use Committee.  Lambs were males 
from Finn x Dorset genotype.  They were born from ewes selected for aseasonal 
breeding and prolificacy at the Cornell Teaching and Research Farm. 
Forty-six lambs were classified at birth on the basis of their body weight as IUGR 
(<3.0 kg, n = 23) or Normal weight (>4.0 kg, n = 23).  The actual birth weight of IUGR 
and Normal lambs were 2.6 kg and 4.1 kg (P<0.001). IUGR lambs also had shorter 
crown-rump length (CRL) than Normal lambs at birth (44.5 vs. 50 cm; P<0.001).  Lambs 
were towel-dried, weighed and bottle-fed artificial colostrum (LandO’Lakes®) 
reconstituted in warm water at the rate of 60 g/kg body weight (BW).  Animals were 
transported immediately to the Cornell University Large Animal Research and Teaching 
Unit and housed in individual cages (75 cm width x 80 cm length x 80 cm height) at 
constant temperature (25° to 27 °C) and photoperiod (light on between 0700 and 1900 
h).  
Four Normal and four IUGR lambs were killed within 4 hours of birth and served 
as reference groups for body composition at birth.  Remaining IUGR and Normal lambs 
were randomly assigned to receive unlimited amounts of a Low Fat (LF; 22% of dry 
matter (DM)) or a High Fat (HF; 38% of DM) milk replacer (Milk Specialties Global, 
Carpentersville, IL Table 3.1).  Two lambs receiving the LF diet were removed from the 
experiment, one IUGR lamb that developed an intestinal infection and one Normal lamb 
that developed a lung infection.  A first group of Normal (n = 15) and IUGR (n = 15) 
lambs was killed at 14 days of age.  An additional group of 3 IUGR-LF and 3 IUGR-HF 
lambs was killed at the live weight (LW) reached by Normal lambs at 14 days of life (8.5 
kg).   
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Table  3.1  Nutrient composition of milk replacers. 
 
 
 
 
 
 
 
 
aLow fat (LF) and high fat (HF) milk replacers.  
 
 Milk replacera 
Nutrient LF HF 
 --- per kg dry matter --- 
   
Gross energy, Mcal 5.54 6.54 
Crude protein, g 301 276 
Fat, g 218 380   
Nitrogen free extract, g 411 287 
Ash, g 70 56 
Vitamin A, KIU 50.67 50.71 
Vitamin D3, KIU 12.21 12.21 
Vitamin E, IU 124 124 
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Procedures during the experiment were as follows: both replacers were 
reconstituted with water at 18.8% DM and served at 0900 h.  They were replenished if 
needed at 1600 and 2000 h.  Offered volume was incrementally adjusted on a daily 
basis.  CRL was measured at birth and on postnatal day 5, 10 and 14.  BW was 
recorded daily at 1600 h.  Blood samples were obtained by jugular venipuncture within 2 
h of birth and at 1600 h on postnatal days 1, 3, 5, 7, 9, 11, 13 and 14.  Blood samples 
were collected in 6-ml tubes containing 90 USP lithium heparin.  Plasma was prepared 
by centrifugation and stored at -20°C until analyzed for glucose and hormones. 
Tissue collection and body composition.  Lambs were killed by lethal 
jugular injection of sodium pentobarbital (88 mg/kg LW; Virbac AH, Inc. TX).  The head 
was severed immediately between the cranium and the first cervical vertebrae and 
processed for isolation of the hypothalamus (25).  Blood was collected and weighed.  
The gastrointestinal (GI) tract was dissected and weighed before and after contents 
were removed.  Omental, perirenal, retroperitoneal and pericardial fat depots were 
dissected and weighed separately.  The viscera fraction was obtained by combining GI 
tract, visceral fat depots, visceral organs (respiratory tract, heart, liver and spleen) and 
blood whereas the carcass fraction consisted of the carcass (without the head), skin and 
hoofs. 
Each fraction was ground separately by extrusion through grinding plates 
(Viscera: 2x through a 13-mm plate and 3x through a 4-mm plate; Carcass: 1x through a 
50-mm kidney plate, 3x through a 13-mm plate and 3x through a 4-mm plate).  A 250 g 
subsample of each fraction was freeze-dried for determination of dry matter.  The freeze-
dried samples were then pulverized with dry ice using a Waring blender and stored at -
20°C until analyzed for nitrogen, ether extract and ash content.  Nitrogen content was 
measured by macro-Kjeldahl digestion (26) with steam distillation into boric acid using a 
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Kjeltec 2300 (FOSS Analytical AB, Sweden).  Crude protein (CP) of body fractions was 
calculated as nitrogen (N) x 6.25.  Fat content of body fractions was determined by 
petroleum-ether extraction (27).  Ash content was determined by incinerating samples in 
a furnace at 506 °C for 16 hours.  All samples were analyzed in duplicate.  Milk replacers 
were analyzed similarly except that a factor of 6.38 was applied to N content to calculate 
CP due to its amino-acid profile (28).  Fat content of milk replacer was measured by an 
hexane/isopropanol extraction (29). 
Glucose and hormones analyses.  Plasma glucose was measured by the 
glucose oxidase method (510A, Sigma Chemical, St. Louis, MO) (23).  Total plasma 
thyroxine (T4) was measured using a commercial solid-phase radioimmunoassay (RIA) 
(Coat-a-Count, Siemens, Germany) previously validated in the sheep (30).  Internal RIA 
previously validated with ovine plasma were used to measure the plasma concentration 
of insulin, leptin and IGF-1 (23, 31).  These RIA use bovine proteins for iodination and 
standards.  The insulin RIA was performed with a guinea pig anti-bovine insulin primary 
antibody (Sigma I-6136) and a goat anti-guinea pig secondary antibody (Equitech-Bio 
Inc., Kerrville, TX) (31).  The leptin RIA was described previously (31).  For IGF-1, IGF-
binding proteins were first removed by ethanol-acetic acid-acetone extraction.  The IGF-
1 concentration of supernatant was then analyzed using an assay based on a rabbit anti-
human IGF-1 primary antibody (lot AFP4892898; National Hormone and Peptide 
Program) and a caprine anti-rabbit γ-antibody (lot 12515, Biotech Source Inc.) (23).  
Inter-assay and Intra-assay coefficients of variation were less than 7% for all assays.   
Calculations.  Feed intake was calculated by subtracting unconsumed milk 
replacer from the previous feed allowance.  Average daily gain (ADG) was calculated for 
each individual as the slope of the regression of body weight over time.  Relative intake 
and fractional weight gain (FWG) were calculated by dividing daily intake or BW gain by 
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the BW of the previous day, respectively.  Metabolic body weight (MBW) was calculated 
by scaling live body weight to the 0.58 power.  According to indirect calorimetry work 
conducted by Graham et al. (32), this exponent relates BW more closely to fasting 
metabolic rate in neonatal lambs than the commonly used 0.75.  In this experiment, 
empty body weight (EBW) is the sum of wet viscera and beheaded carcass weights.  
Indices of fatness (mass of fat depots, visceral fat or carcass fat) were expressed as a % 
of EBW.  Composition of the EBW was calculated from the composition of viscera and 
carcass fraction.  
Statistical analyses.  Averages were calculated over the 14-day period for 
intake and growth data (e.g. intake, FWG, etc.).  Averages and cumulative end-point 
data (e.g. BW gain, ADG and body composition data) were analyzed by a model 
accounting for Body size (Normal vs. IUGR), Diet (LF vs. HF) and their interaction using 
the ANOVA procedure.   
A MIXED procedure of SAS was used to analyze repeated measures data (feed 
intake, body weight, metabolic data).  Our model accounted for BS, Diet, Day and their 
interactions as fixed effects and lamb as the random effect.  In presence of Diet x Day 
interactions, linear and quadratic regressions were performed within Diet category.  
Statistical significance was set at P<0.05 for main effects and P<0.10 for interactions.  
Statistical tendency was set at P<0.10 for main effects and P<0.15 for interactions. 
 
.
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Results  
Intake.  DM and energy intake data were averaged over the 14-day 
experimental period and reported in table 3.2.  IUGR lambs had lower voluntary DM 
intake than Normal lambs (Diet, P<0.001) but the opposite effect was observed when 
intake was expressed relative to LW (Diet, P<0.001).  Dietary fat content had no effect 
on either variable.  
BS had similar effects on energy intake:  IUGR lambs consumed less energy 
than Normal lambs when analyzed in absolute terms but more when energy intake was 
normalized to LW (Diet, P<0.001 for both variables).  Effects of BS on energy intake 
were eliminated by correcting for MBW.  Dietary fat content increased absolute energy 
intake as well as energy intake corrected for LW or MBW (P<0.01 or less for all).  BS x 
Diet interactions were not detected for any dry matter or energy intake values.  
Finally, we asked whether BS and Diet effects varied over time by analyzing 
intake responses as repeated measures over the period of treatment.  This analysis 
revealed the presence of the same Diet x Day interaction for all intake responses 
(P<0.15 or less).  The nature of this interaction is illustrated by the profiles of absolute 
DM intake (Fig. 3.1) and energy intake corrected for MBW (Fig. 3.2).  In brief, dry matter 
intake and energy intake corrected for MBW increased linearly for the LF diet (linear time 
effect, P<0.001) whereas they plateau by day 7 to 9 for the HF diet (quadratic time effect, 
P<0.001). 
Growth.  Growth data averaged over the 14 d treatment period are given in 
Table 3 and the cumulative growth curves are shown in Fig. 3.3.  IUGR and Normal 
lambs grew at steady rates throughout the entire treatment period (Fig. 3.3).  IUGR 
lambs had a 20% lower ADG than Normal lambs (Table 3.3; BS, P<0.001), resulting 
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Table  3.2  Effect of birth size and dietary fat content on dry matter and energy intake between birth and slaughter on day 14 
of postnatal life. 
 Normalb  IUGRb  Probability levelc 
Variablea LF HF  LF HF SD BS Diet BS x Diet 
Dry matter intake          
Absolute, g/d 276 280  228 209 31 <0.001 NS NS 
Relative to LW, g/kg  d 42 43  50 50 4 <0.001 NS NS 
Energy intake          
Absolute, kcal/d 1,529.8 1,831.6  1,264.4 1,369.7 186.7 <0.001 <0.01 NS 
Relative to LW, kcal/kg  d 232.0 283.6  278.8 328.0 26.3 <0.001 <0.001 NS 
Relative to MBW, kcal/kg0.58d 504.1 614.5  519.1 585.9 56.6 NS <0.001 NS 
aLW, live weight; MBW, metabolic body weight (kg0.58). 
bNormal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat (LF) or high fat (HF) milk replacer between 
birth and slaughter on day 14 of life (n = 7-8 lambs per treatment). 
cType I error probability for birth size (BS), diet (Diet) and their interaction (BS x Diet).  NS = P>0.05 for main effects and P>0.15 for 
the interaction.  
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Normal size (Normal) or intrauterine growth-retarded (IUGR) lambs were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment).  Voluntary dry matter intake was recorded daily.  The pooled SE 
was 16.4 for n = 8 and 18.5 for n = 7.  Significant effects of birth size (BS), and day (Day) 
and Diet x Day are reported.  All other effects were non-significant.
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Figure  3.1  Effect of birth size and dietary fat content on voluntary dry matter 
intake between birth and slaughter on day 14 of postnatal life. 
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Normal size (Normal) or intrauterine growth-retarded (IUGR) lambs were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment).  Caloric intake was measured daily and expressed as ratio of 
metabolic body weight (kg0.58).  The pooled SE was 38.9 for n = 8 and 41.5 for n = 7.  
Significant effects of dietary treatment (Diet), day (Day) and Diet x Day interaction are 
reported.  All other effects were non-significant. 
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Figure  3.2  Effect of birth size and dietary fat content on caloric intake adjusted 
for metabolic body weight between birth and slaughter on day 14 of postnatal. 
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Normal size (Normal) or intrauterine growth-retarded (IUGR) lambs were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment).  Body weights were recorded daily and cumulative weight gain 
calculated by difference from body weight at birth.  The pooled SE was 0.11 for n = 8 
and 0.12 for n = 7.  Significant effects of birth size (BS), day (Day) and BS x Day 
interaction are reported.  All other effects were non-significant. 
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Figure  3.3  Effect of birth size and dietary fat content on cumulative weight 
gain between birth and slaughter on day 14 of postnatal life. 
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Table  3.3  Effect of birth size and dietary fat content on lamb growth between birth and slaughter on day 14 of postnatal life. 
 Normalb  IUGRb  Probability levelc 
Variablea LF HF  LF HF SD BS Diet BS x Diet 
Cumulative weight gain, kg 4.37 4.30  3.76 3.50 0.46 <0.001 NS NS 
Final weight, kg 8.49 8.46  6.52 5.92 0.59 <0.001 NS NS 
ADG, kg/day 0.31 0.32  0.25 0.27 0.03 <0.001 NS NS 
FWG, % day 5.7 5.9  6.9 6.8 0.6 <0.001 NS NS 
CRL gain, cm 8.6 10.8  9.1 10.9 3.2 NS NS NS 
Final CRL, cm 58.1 60.8  54.2 54.4 2.9 <0.001 NS NS 
aADG, average daily gain; FWG, fractional weight gain; CRL, crown rump length. 
bNormal size (Normal) or intrauterine growth-retarded (IUGR) lambs were fed a low fat (LF) or high fat (HF) milk replacer between 
birth and slaughter on day 14 of life (n = 7-8 lambs per treatment). 
bType I error probability for birth size (BS), diet (Diet) and their interaction (BS x Diet).  NS = P>0.05 for main effects and P>0.15 for 
the interaction. 
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in progressively diverging cumulative growth curves (Fig. 3.3; BS x Day, P<0.001).  
Accordingly, IUGR lambs also had lower final cumulative gain and remained lighter at 
slaughter (BS, P<0.001).  The average weight difference between Normal and IUGR 
lambs actually grew from 1.6 kg at birth to 2.0 kg by day 14.  Nevertheless, the fractional 
growth rate (FGR) of IUGR lambs was 18% higher than that of Normal lambs (BS, 
P<0.001).  Finally, both groups had similar crown-rump growth during the treatment 
period and therefore IUGR remained ~9% shorter at slaughter (BS, P<0.001).  Diet did 
not have any effects on any growth parameters.  
Body composition.  At birth, IUGR and Normal lambs had similar fat (1.6 vs. 1.6%) 
and ash content (15 vs. 17%) in the EBW, but protein content was higher in Normal than 
IUGR lambs (18.3 vs. 17.0%, P<0.02).  Effects of BS and Diet on EBW characteristics at 
day 14 of postnatal life are given in Table 3.4.  IUGR lambs had a 27% lower EBW mass 
than Normal lambs (BS, P<0.001), and a 5% higher visceral fraction in the EBW (BS, 
P<0.03).  Diet did not alter these variables. 
Composition analysis was performed separately on the visceral and carcass 
fractions of EBW.  In the viscera fraction, both the IUGR condition and the HF diet 
increased fat content (Fig. 3.4; BS and Diet, P<0.03 or less).  For example, the visceral 
fat content was 42% higher in IUGR than Normal lambs on the LF diet, whereas it was 
58% higher when Normal lamb were fed the HF rather than the LF diet (Fig. 3.4).  These 
data are supported by dissection of the individual visceral fat depots at slaughter (Fig. 
3.5).  With the single exception of the pericardial fat depot, both BS and Diet increased 
the fraction of the EBW occupied by each depot (BS and Diet, P<0.04 or lower). 
In the carcass, effects of BS and Diet were less obvious, reflecting in part a 
blunted increase in fat content in IUGR lambs receiving the HF diet (Fig. 3.4; BS x Diet,  
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Table  3.4  Effect of birth size and dietary fat content on body composition on day 14 of postnatal life. 
 Normalb  IUGRb  Probability levelc 
Variablea LF HF  LF HF SD BS Diet BS x Diet 
EBW, kg 7.10 7.17  5.42 4.95 0.51 <0.001 NS NS 
          
Carcass (% EBW) 77.4 77.9  76.8 76.4 1.1 <0.03 NS NS 
Viscera (% EBW) 22.6 22.1  23.2 23.6 1.1 <0.03 NS NS 
      
Composition of EBW          
Water % 72.6 68.9  72.3 70.3 1.6 NS <0.001 NS 
Fat % 6.8 10.6  8.1 10.1 1.6 NS <0.001 NS 
Protein % 17.5 17.3  16.6 16.4 0.7 <0.01 NS NS 
Carbohydrate % 0.4 0.4  0.5 0.7 0.3 0.05 NS NS 
Ash % 2.8 2.7  2.6 2.5 0.3 0.02 NS NS 
aEBW, empty body weight. 
bNormal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat (LF) or high fat (HF) milk replacer between 
birth and slaughter on day 14 of life (n = 7-8 lambs per treatment). 
cType I error probability for body weight category at birth (BWC), diet (Diet) and their interaction (BW x Diet).  NS = P>0.05 for main 
effects and P>0.15 for the interaction.  
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a Low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment).  Fat was measured separately in carcass and viscera and 
expressed as a % of empty body weight (EBW).  Each bar represents the mean ± SE of 
7-8 lambs. The significant effects of birth size (BS), diet (Diet) and their interaction (BS x 
Diet) are reported. 
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Figure  3.4  Effect of birth size and dietary fat content on viscera and carcass. 
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat (LF) or high fat (HF) 
milk replacer between birth and slaughter on day 14 of life (n = 7-8 lambs per treatment).  Fat depots were 
dissected, weighed, and expressed as % of empty body weight (EBW).  Each bar represents the mean ± SE 
of 7-8 lambs. The significant effects of birth size (BS) and diet (Diet) are reported. 
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Figure  3.5  Effect of birth size and dietary fat content on visceral depots. 
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P<0.09).  As a consequence, the stimulatory effects of the IUGR condition on fat content 
were not significant in the EBW (Table 3.4).  This lack of BS effect in the EBW was 
associated with attenuation in the retention of dietary fat and energy in IUGR lambs fed 
the HF diet (Fig. 3.6; BS x Diet, P<0.04). Effects of BS and Diet on the EBW content of 
the other chemically defined components are also reported in Table 3.4.  IUGR lambs 
had slightly lower protein and ash content and slightly higher carbohydrate content (BS, 
P<0.05 or less).  The only effects of the HF diet were to increase the fat content of the 
EBW and to cause the opposite for water content (Diet, P<0.001). 
Metabolic indices.  Blood samples were obtained at birth before ingestion of 
colostrum and analyzed for the plasma concentration of glucose and metabolic 
hormones (Table 3.5).  Consistent with a state of fetal undernutrition, IUGR lambs had 
lower plasma concentration of glucose and IGF-1 than Normal lambs (P<0.02 or less) 
but had similar plasma leptin.  Moreover, plasma insulin was only detectable in Normal 
lambs.  IUGR lambs also had lower plasma T4 (P<0.001) and plasma insulin levels that 
were below the detection level of the assay.  Similar analyses were performed on 
plasma samples obtained between day 1 and 14 of treatment.  The LF diet caused a 
reduction in plasma glucose but only on day 1 (Fig. 3.7; Diet x Day, P<0.006).  Normal 
lambs experienced an elevation in plasma insulin concentration by the end of treatment 
versus lower and steady concentration in IUGR lambs (Fig. 3.8; BS x Day, P<0.04).  In 
the case of IGF-1 the plasma concentration rose until day 9 in Normal lambs whereas it 
was still rising by day 14 in IUGR lambs (Fig. 3.9; BS x Diet, P<0.04).  Plasma leptin 
remained relatively steady over time irrespective of BS and tended to be higher in lambs 
fed the HF diet (Fig. 3.10; Diet, P=0.14).  The most prominent effects of treatments were 
on plasma T4 (Fig. 3.11), with effects of both BS and Diet varying over time.  IUGR 
lambs had lower plasma T4 than Normal lambs for the first 3 days irrespective of Diet,  
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a Low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment).  Fat was measured by chemical method and energy by bomb 
calorimetry.  Each bar represents the mean ± SE of 7-8 lambs. The significant effects of 
birth size (BS), diet (Diet) and their interaction (BS x Diet) are reported. 
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Figure  3.6  Effect of birth size and dietary fat content on fat and energy retention. 
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Table  3.5  Effect of birth size on glucose and the concentration of selected metabolic hormones at birth. 
  Birth Size    
Variable  Normala  IUGRa  SD Probability levelb 
Glucose, mg/dl  58  35  25 <0.02 
Insulin, ng/ml  0.11  <0.10  0.2 NS 
IGF-1, ng/ml  147  93  43 <0.01 
Leptin, ng/ml  4.0  3.7  1.0 NS 
T4, nmol/l  163  109  28 <0.001 
aNormal size (Normal) or intrauterine growth-retarded lambs (IUGR) were sampled within 2 hours of birth before consuming 
colostrum (n = 15 lambs per group). 
bType I probability error.  NS = P>0.05.  
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-
8 lambs per treatment). Plasma samples were obtained between 1600 and 1700 h.  
Pooled SE was 6.6 for n = 8 and 7.1 for n = 7.  Significant effects of day (Day) and the 
interaction between Diet and Day are reported.  All other effects were non-significant.   
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Figure  3.7  Effect of birth size and dietary fat content on plasma glucose 
concentration between day 1 adn 14 of postnatal life. 
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-
8 lambs per treatment). Plasma samples were obtained between 1600 and 1700 h.  
Pooled SE was 0.06 for n = 8 and 0.07 for n = 7. Significant effects of birth size (BS), 
day of treatment (Day) and their interaction are reported.  All other effects were non-
significant. 
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Figure  3.8  Effect of birth size and dietary fat content on plasma insulin 
concentration between day 1 and day 14 of postnatal life. 
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Normal size (Normal) or intrauterine growth-retarded (IUGR) lambs were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment). Plasma samples were taken between 1600 and 1700 h.  Pooled 
SE was 27 for n = 8 and 29 for n = 7.  Significant effect of birth size (BS), day (Day) and 
their interaction are reported.  All other effects were non-significant. 
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Figure  3.9  Effect of birth size and dietary fat content on plasma IGF-1 
concentration between day 1 and 14 of postnatal life. 
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Figure  3.10  Effect of birth size and dietary fat content on plasma leptin 
concentration between day 1 and 14 of postnatal life. 
Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment). Plasma samples were taken between 1600 and 1700 h.  Pooled 
SE was 0.4.  No effects were significant. 
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Normal size (Normal) or intrauterine growth-retarded lambs (IUGR) were fed a low fat 
(LF) or high fat (HF) milk replacer between birth and slaughter on day 14 of life (n = 7-8 
lambs per treatment). Plasma samples were taken between 1600 and 1700 h.  Pooled 
SE was 9.1 for n=8 and 9.9 for n = 7.  Significant effects of birth size (BS), diet (Diet), 
day (Day) and their interactions are reported.  All other effects were non-significant. 
 
 
0
50
100
150
200
250
300
0 3 6 9 12 15
Pl
as
m
a 
T4
 (n
m
ol
/l)
 
Postnatal age (d) 
Normal-LF
Normal-HF
IUGR-LF
IUGR-HF
BS  P<0.01 
Diet  P<0.01 
Day  P<0.001 
BS x Day P<0.01 
Diet x Day P<0.001 
Figure  3.11  Effect of birth size and dietary fat content on plasma T4 
concentration between day 1 and 14 of postnatal life. 
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followed by disappearance of the BS effect by day 14 (BS x Day, P<0.01).  Dietary fat on 
the other hand had no effect over the first 3 days but caused increased plasma T4 
irrespective of BS by day 14 (Diet x Day, P<0.001). 
Body composition at fixed live weight.  IUGR lambs were 27% lighter than 
Normal lambs by the end of treatment on day 14 of life (6.2 vs. 8.5 kg), and therefore BS 
effects on fatness may be underestimated.  To assess whether this is the case, a 
second group of IUGR lambs were slaughtered when they reached 8.5 kg LW.  IUGR 
fed the LF diet tended to reach this target weight sooner than their HF counterparts (18.7 
vs. 21.3 days, P=0.07).  Body composition analysis was performed exactly as described 
earlier and compared to Normal lambs killed on day 14.  When compared in this manner, 
neither BS nor Diet affected EBW (Fig. 3.12A).  The fraction of EBW occupied by viscera 
was increased in IUGR lambs fed the HF diet, whereas the reciprocal effect was seen 
for the carcass fraction (Fig. 3.12B and results not shown, BS x Diet, P<0.02).  As seen 
at 14 days of age, IUGR lambs had higher fat content in the viscera than Normal lambs 
irrespective of Diet (Fig. 3.12C, BS, P<0.001).  This fat content difference was now 
significantly larger than seen at day 14 of age:  when fed the LF diet, IUGR had a 
greater than 2 fold difference (Fig. 3.12C) relative to Normal lambs at 8.5 kg vs. 1.3 fold 
difference at day 14 (Fig. 3.4).  IUGR lambs also had heavier visceral fat depots than 
Normal lambs on both diets, except for the pericardial fat depot (Fig. 3.12D and results 
not shown).  Finally, IUGR also had more fat in the carcass at 8.5 kg (Fig. 3.12C) 
whereas this effect was not significant at 14 days of age (Fig. 3.4). 
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Normal size (Normal; n = 7-8 per group) or intrauterine growth-retarded lambs (IUGR; n = 3 per 
treatment) were fed a low fat (LF) or high fat (HF) milk replacer between birth and slaughter at the 
fixed weight of 8.5 kg.  A. Empty body weight (EBW).  B. Viscera fraction expressed as % of 
EBW.  C. Fat content of viscera and carcass fractions.  Fat was measured separately in carcass 
and viscera and expressed as % of EBW.  D. Mass of omental and all visceral fat depots.  Fat 
depots were dissected, weighed, and expressed as a % empty body weight (EBW). Each bar 
represents the mean ± SE of 3, 7 or 8 lambs. The significant effects of birth size (BS), diet (Diet) 
and their interaction (BS x Diet) are reported. 
BS x Diet,     P<0.02 
 
BS,           P <0.001 
Diet,         P <0.01 
BS,           P <0.001 
Diet,          P <0.001 
BS,           P <0.001 
Diet,          P <0.002 
BS,           P <0.001 
Diet,          P <0.005 
            LF 
            HF 
A                                  B 
C 
D 
Figure  3.12  Effect of birth size and dietary fat content on carcass and visceral 
parameters at 8.5 kg live weight. 
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Discussion. 
In this study we used an IUGR model arising naturally in prolific ewes (21).  The 
cause of the IUGR condition in this model is fetal undernutrition, which results from the 
combination of 2 factors: first, ewes have a fixed number of uterine sites where fetal and 
maternal tissues meet to form the placentome, the functional nutrient exchange unit of 
the placenta.  It follows that the number of placentomes serving each fetus decreases 
with increasing litter size, inevitably leading to smaller placentas for one or more fetuses 
in litters of 3 or 4 lambs (33).  This placental insufficiency induces a state of fetal 
undernutrition and growth retardation mainly during the last third of gestation when 80% 
of fetal growth occurs (34).  Consistent with fetal undernutrition, IUGR lambs had 
reduced concentration of nutritionally-regulated plasma variables at birth (i.e. glucose, 
IGF-1 and insulin).  The 37% reduction in birth size in our study agrees with the 20-50% 
reduction obtained in other sheep models limiting placental size or function, such as 
artificial placental embolization (35), endometrial carunclectomy (36), overnutrition of 
pubertal ewes or hyperthermia (37). 
Studies performed mostly in rodents have shown that the IUGR condition has 
long-term effects on postnatal energy metabolism such as increased appetite, lower 
energy expenditure and overall adiposity (38–40).  These studies have also shown that 
HF diets exacerbate these detrimental effects (38, 41).  All of this work however, has 
been performed during the post-weaning period and the interaction between IUGR and 
caloric density during early postnatal life remains unknown.  We sought to investigate 
this question by rearing Normal and IUGR lambs with artificial milk varying in fat content. 
Similar to the results obtained with this model by Greenwood et al (21), IUGR 
lambs had higher relative dry matter and caloric intake during the first 14 days of life.  
When adjusted for MBW, however, differences in relative energy intake between IUGR 
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and Normal lambs disappeared, implying that intake is not energetically disproportionate 
in IUGR lambs.  This adjustment is used to normalize the fasting or basal energy 
expenditure per unit of body weight (kg) across animals differing substantially in size.  
We chose the 0.58 exponent because Graham et al. (32) showed that it offers a closer 
association to basal metabolic rate in milk-fed lambs than the commonly used 0.75 
exponent.  It would be interesting to determine whether the application of this 
normalizing procedure would eliminate differences in intake associated with the IUGR 
condition in other species as well. 
A second important set of observations relate to the effects of dietary fat content 
on intake.  The absence of caloric density effects on the average feed intake suggests 
that homeostatic regulation of energy consumption does not fully operate during this 
early stage of postnatal life in sheep.  Other investigators have made the same 
observation in small ruminants of normal birth size that were offered milk replacers of 
differing in fat content (42, 43).  Furthermore, the same phenomenon was observed in 
studies conducted with newborn infants (44, 45).  In contrast, Corl et al. (46) reported a 
reduction in intake when newborn piglets were offered a 25% fat diet compared to a 3% 
diet.  It is possible that such extreme dietary treatment would also trigger intake 
regulation in neonatal sheep.  Finally, our data suggest that the profile of intake over 
time follows a quadratic relation in HF-lambs versus a linear relation in LF-animals.  
These data are consistent with emergence of a calorie-based appetite control after the 
first week of age.  We did not observe, however, any differences between Normal and 
IUGR lambs with respect to this phenomenon. 
The significant 18% increase in fractional weight gain observed in IUGR lambs 
indicates that these animals developed accelerated weight gain or ‘catch-up’ growth 
during the first 14 days of life.  It is well established that human infants experiencing 
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catch-up growth, have higher risk of developing obesity and non-communicable 
diseases later in life (47, 48).  Furthermore, catch up growth in mice not only increased 
adiposity but also reduced their lifespan dramatically (49, 50).  De Blasio et al. (36, 51) 
observed that IUGR lambs reared naturally catch-up with the weight of their normal 
controls at approximately day 35 of age.  At 43 days of life, these IUGR animals had 50% 
heavier visceral fat depots than control animals but the timing of the effect was not 
established.  On the other hand, Greenwood et al. (21) demonstrated that total body 
fatness of ad libitum-fed IUGR lambs was 33% higher than normal lambs as early as 
postnatal day 11.  Our data shows that visceral fat content is increased by the IUGR 
condition as early as day 14 of life, and effects are independent of the fat content of the 
diet. Negative effects of the IUGR condition on adiposity were most evident in lambs fed 
the LF diet. These lambs showed an increase of 42% in visceral fatness.  This was 
supported by the significantly higher relative weight of all visceral fat depots dissected at 
slaughter.  Remarkably, these effects of the IUGR condition on fat deposition increased 
dramatically when comparisons were performed at the similar BW of 8.5 kg.  For 
instance, IUGR lambs offered the LF diet had a greater than two fold increase in visceral 
fat and in the mass of the visceral fat depots relative to their normal counterparts.  
Moreover, IUGR lambs also had significantly more fat in the carcass.  Finally, these 
differences in fatness were achieved after only 3 weeks of life.  It is likely that the obesity 
penalty of the IUGR condition is significantly higher at maturity.  
Finally, we profiled plasma glucose and selected metabolic hormones as a first 
step to understand the predisposition for fat accretion in IUGR.  The plasma 
concentrations of glucose and insulin were not very instructive, perhaps because plasma 
samples were obtained without a standardized fasting period.  In contrast, plasma 
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concentrations of T4 and leptin are not acutely affected by feeding and both provided 
information relevant to the IUGR condition. 
As observed previously in sheep and infants (52–54), IUGR lambs had lower 
plasma T4 plasma levels at birth.  Hypothyroxinemia continued for the length of the 
experiment in IUGR lambs fed the LF diet and those are the IUGR lambs with the 
highest fat deposition relative to their matched counterparts.  It is well known that sheep, 
as well as humans, rely on adaptive thermogenesis by brown adipose tissue (BAT) to 
maintain an adequate temperature at birth (55).  A normal thyroid function is essential to 
develop such thermogenesis in the newborn lamb (56, 57).  In the past, researchers 
have demonstrated the association between the evident hypothyroidism observed in 
IUGR lambs and their incapacity to initiate this process to maintain adequate body 
temperature at birth (57, 58).  Moreover, key evidence indicates that prenatally 
thyroidectomized lambs show inadequate thermogenesis, reduced UCP-1 content and 
increased lipid deposition in perirenal depots (59).  Importantly, the rate of lipid 
deposition increases as soon as thermogenic capacity of BAT decreases in early life 
(60).  IUGR animals also mobilize less NEFA upon adrenergic stimulation (61), 
presumably due to reduced expression of β2 adrenergic receptor in white adipose tissue 
(62). 
Finally, concentration of thyroid hormones is positively associated to energy 
expenditure in adult animals (63, 64).  Higher concentration of thyroid hormones is 
associated with greater energy expenditure by uncoupled oxidation of lipids in muscle, 
while hypothyroid states promote lipid retention in adult animals (64, 65). We speculate 
that neonatal hypothyroidism contributes to the increased visceral adiposity observed in 
IUGR lambs.  In fact, the expression of key genes regulating β-oxidation in muscle is 
reduced in IUGR lambs at birth (Ehrhardt and Boisclair, unpublished data).  Moreover, 
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persistently lower T4 concentration found in IUGR-LF lambs could exacerbate this effect, 
leading to a significant increase in perirenal and retroperitoneal adiposity observed in 
these animals.  On the other hand, it was clear that the fatness-promoting effect of the 
HF was blunted in IUGR relative to that of Normal lambs.  This effect was associated 
with a significantly lower apparent retention of dietary fat in this group (44% vs. 50% in 
Normal lambs; results not shown).  The significant effect of dietary fat on the dynamics 
of T4 could be a factor to consider in understanding these differences.  Although we can 
only speculate, the explanation for this observation could range from a lower absorption 
of dietary fat to a relative hypersensitivity to rising T4 levels in the IUGR lambs offered 
the HF diet.  
A second important finding in this experiment is the absence of any notable effect 
of BS on either the average plasma leptin concentration or its profile over time.  Rodents 
experience a 5- to 10-fold increase in plasma leptin concentration during the first two 
weeks of life that is not related to either adiposity or changes in voluntary intake (66). It 
was later determined that this leptin surge had neurotrophic effects and is essential to 
the proper development of axonal projections between hypothalamic centers involved in 
the regulation of energy homeostasis (67).  Interestingly, this neonatal surge of leptin is 
blunted in IUGR offspring born of rat dams subjected to a 50% diet restriction during the 
last third of gestation (68). This endocrine defect is associated with hyperphagia, obesity, 
hyperinsulinemia and hyperleptinemia during adulthood when IUGR offspring are fed a 
high fat diet (38).  Interestingly, leptin treatment of rats during early life (P3 to P13) 
reverses this adverse phenotype (13).  Long et al. (69) recently suggested that sheep, 
like rats and mice, also experience a leptin surge that could be altered by fetal nutritional 
insults and consequently, affect the adult phenotype of the offspring.  Close examination 
of these data show a rise from ~1.8 ng to 2.5 ng/ml between day 5 and 9 of postnatal 
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age.  This is no different than normal daily variation observed previously by others (70, 
71), and more importantly nothing to what is seen in rats (6 to 45 ng/ml) or mice (1 to 10 
ng/ml) (66, 72).  Additionally, this and other studies did not detect any surge in plasma 
leptin in neonatal lambs (31, 73).  Due to the significant differences in developmental 
maturity at birth between precocial and altricial species, any potential neurotrophic effect 
of leptin in the sheep is more likely to occur during intrauterine rather than early life. 
In summary, our study confirmed that the IUGR condition in lambs is associated 
to higher relative intake, accelerated growth and excess adiposity in the immediate 
postnatal life.  On a MBW basis, however, both Normal and IUGR lambs were on the 
same plane of energy consumption.  Moreover, a higher fat diet did not exacerbated 
appetite in IUGR lambs.  Rather, our data suggest that lower energy expenditure could 
be a determinant factor behind the obesity observed in IUGR lambs within the first 
weeks of life. 
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CHAPTER  4 :  EFFECT OF MELANOCORTIN AGONIST TREATMENT ON 
INTAKE, GROWTH AND BODY COMPOSITION OF INTRAUTERINE 
GROWTH RETARDED LAMBS 
 
Introduction 
Greenwood and colleagues (1) characterized the early life phenotype of 
intrauterine growth retarded (IUGR) lambs arising from multifoetal sheep pregnancies 
and reared artificially with milk replacer. These IUGR lambs were born at 60-70% of 
normal weight as a result of undernutrition during the last third of gestation.  Immediately 
after birth, these animals had higher relative intake and dietary fat retention as well as 
lower basal energy expenditure (1).  As a consequence, they were fatter than their 
normal counterparts, particularly when assessed at similar body weight.  We have 
recently extended this work by showing that the IUGR condition promotes visceral lipid 
deposition and that this effect is associated with decreased thyroid hormone levels 
(Chapter 3).  Additionally, IUGR offspring from carunclectomized ewes also developed 
heavier visceral fat depots than control lambs after only 43 days of natural rearing (2, 3).  
Promotion of lipid deposition by the IUGR condition has also been observed in humans 
(4) and is associated with the development of metabolic disorders (5–9).   
Over the last few decades, the central nervous system has been shown to be the 
primary regulator of energy-dependent variables, including all of those found to be 
altered in IUGR offspring (10, 11).  One of the most important circuits involved in central 
regulation of energy homeostasis is controlled by peptides known as melanocortins (MC).  
MC are produced predominantly by neurons located in the arcuate (ARC) region of the 
hypothalamus and include the proteolytic product of the POMC gene α-MSH, and Agouti 
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related peptide (AGRP) (12, 13).  α-MSH and AGRP are subject to reciprocal regulation 
by peripheral cues indicative of energy status such as leptin (14).  Both, peptides bind to 
melanocortin receptor -3 and -4 (MC4R), located in distal hypothalamic nuclei such as 
the PVN and LHA (15) with α-MSH acting as an agonist and AGRP as an antagonist.  
Energy dependent variables such as appetite, energy expenditure and thyroid hormone 
production are regulated by these reciprocal actions of α-MSH and AGRP (16). 
The IUGR condition, however, has been found to alter the ability of leptin and 
other cues to regulate the activity of the MC system leading to hyperphagia and obesity 
in rodents (17–19).  This has prompted efforts to directly activate this system via 
exogenously administrated MC agonist in an effort to normalize energy metabolism.  MC 
agonists have been successfully used in various adult models of disrupted energy 
expenditure and obesity (20, 21).  It is unknown, however, whether the MC system is 
functional in early postnatal life in the sheep and other precocial mammals and therefore 
whether MC agonists could be used to normalize the energy metabolism of these IUGR 
animals in the immediate postnatal life.  The objectives of this experiment were to 
explore the functionality of the central MC system in the immediate postnatal life and to 
evaluate MC4R’s potential use to correct some of the detrimental phenotypes observed 
in IUGR lambs. 
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Materials and Methods 
Animals and study design.  All experimental procedures were approved by the 
Cornell University Institutional Animal Care and Use Committee.  Lambs were males 
from Finn x Dorset genotype.  They were born from ewes selected for aseasonal 
breeding and prolificacy at the Cornell Teaching and Research Farm. 
Seventeen lambs were selected at birth prior to suckling on the basis of their 
body weight as IUGR (<3.0 kg) or Normal weight (>4.0 kg).  The average birth weight of 
selected lambs was 2.46 kg for IUGR lambs (n = 12) and 4.27 kg for Normal lambs (n = 
5) (P<0.001).  Lambs were towel-dried, weighed and bottle-fed colostrum replacer 
(LandO’Lakes®) reconstituted in warm water at the rate of 60 g/kg BW.  Animals were 
transported immediately to the Cornell University Large Animal Research and Teaching 
Unit and housed in individual cages (75 cm width x 80 cm length x 80 cm height) at 
constant temperature (25° to 27 °C) and photoperiod (light on between 0700 and 1900).  
Lambs were offered unlimited amounts of a milk replacer (Milk Specialties Global, 
Carpentersville, IL; Table 4.1) throughout the experiment. 
The period between birth and day 3 was used to collect basal data on feed intake, 
growth and plasma concentration of glucose and selected metabolic hormones.  
Treatments were administered between day 4 and 15 of postnatal life.  IUGR lambs 
were treated for 12 days with 450 nmol/kg LW  day of the MC4R agonist BIM-22493 
(IUGR-MC4R, n = 6) or excipient solution (IUGR, n = 6).  BIM-22493 was solubilized in 
excipient solution (0.9% saline, 0.1% BSA and 5% N,N-dimethylacetamide) at the 
concentration of 2.3 μmol/ml as recommended by the supplier (Biomeasure Incorporated, 
IPSEN, Milford, MA).  The daily dose was administered as 3 equal subcutaneous 
injections at 0 h, 0800 h and 1600 h.  A group of Normal lambs was injected with  
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Table  4.1  Nutrient composition of milk replacer. 
 
 
 
 
 
 
 
 
 
 
 
Nutrient -- per kg dry matter -- 
Gross energy, Mcal 5.54 
Crude protein, g 301 
Fat, g 218 
Nitrogen free extract, g 411 
Ash, g 70 
Vitamin A, KIU 50.67 
Vitamin D3, KIU 12.21 
Vitamin E, IU 124 
94 
 
excipient solution (Normal, n = 5) and served as an additional control.  The last injection 
was administered at 0800 h on day 15.  
Experimental procedures during the basal and treatment periods were as follows.  
The milk replacer was reconstituted with water at 18.8% dry matter (DM) and served at 
0900 h with replenishment at 1600 and 2000 h if needed.  Offered volume was adjusted 
on daily basis as needed.  Crown-rump length was measured on day 5, 10 and 15.  
Body weight was recorded daily at 1600 h.  Blood samples were obtained by jugular 
venipuncture within 2 h of birth and at 1600 h of postnatal days 1, 3, 5, 7, 9, 11 and 13.  
Blood samples were collected in 6-ml tubes containing 90 USP lithium heparin and 
plasma was prepared by centrifugation.  Plasma samples were stored at -20°C until 
analyzed for glucose and hormones. 
Tissue collection and analysis of body composition.  Lambs were killed on day 15 
of life by lethal intra-jugular injection of sodium pentobarbital (88 mg/kg LW; Virbac AH, 
Inc. TX).  The head was severed immediately between the cranium and the first cervical 
vertebrae and processed for isolation of the hypothalamus.  Blood was collected and 
weighed.  The gastrointestinal (GI) tract was dissected and weighed before and after 
contents were removed.  Omental, perirenal, retroperitoneal and pericardial fat depots 
were dissected and weighed separately.  The viscera fraction was obtained by 
combining the empty GI tract, visceral fat depots, visceral organs (respiratory tract, heart, 
liver and spleen) and blood.  The carcass fraction consisted of the carcass (without the 
head), skin and hoofs. 
Each fraction was grounded separately by extrusion through grinding plates 
(Viscera: 2x through a 13-mm plate and 3x through a 4-mm plate; Carcass: 1x through a 
50-mm kidney plate, 3x through a 13-mm plate and 3x through a 4-mm plate).  A 250 g 
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subsample of each fraction was freeze-dried for determination of dry matter.  The freeze-
dried samples were then pulverized with dry ice using a Waring blender and stored at -
20°C until analyzed for nitrogen, ether extract and ash content.  Nitrogen content was 
measured by macro-Kjeldahl digestion (22) with steam distillation into boric acid using a 
Kjeltec 2300 (FOSS Analytical AB, Sweden).  Crude protein (CP) was calculated as 
nitrogen (N) x 6.25.  Fat content of body fractions was determined by petroleum-ether 
extraction (23).  Ash content was determined by incinerating samples in a furnace at 
506 °C for 16 hours.  All samples were analyzed in duplicate.  Milk replacers were 
analyzed similarly except that a factor of 6.38 was applied to N content to calculate CP 
due to its amino-acid profile (24).  Fat content of milk replacer was measured by a 
hexane/isopropanol extraction (25). 
Analyses of plasma glucose and hormones.  Plasma glucose was measured 
using a commercial glucose oxidase enzymatic assay (510A; Sigma Chemical, St. Louis, 
MO) (26).  Total plasma thyroxine (T4) was measured using a commercial solid-phase 
RIA (Coat-a-Count, Siemens, Germany) previously validated in sheep (27).  Internal RIA 
previously validated with ovine plasma were used to measure the plasma concentration 
of insulin, leptin and IGF-1 (26, 28).  These RIA use bovine proteins for iodination and 
standards.  The insulin RIA was performed with a guinea pig anti-bovine insulin primary 
antibody (Sigma I-6136) and a goat anti-guinea pig secondary antibody (Equitech-Bio 
Inc., Kerrville, TX).  The leptin RIA is based on a primary rabbit antibody raised against 
bovine leptin and a secondary goat antibody raised against rabbit gamma-globulin. For 
IGF-1, IGF-binding proteins were first removed by acid-ethanol extraction.  Supernatant 
was then analyzed using an IGF-1 assay based on a rabbit anti-human IGF-1 primary 
antibody (lot AFP4892898; National Hormone and Peptide Program) and a caprine anti-
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rabbit gamma-antibody (lot 12515, Biotech Source Inc.) (26).  Inter-assay and Intra-
assay coefficients of variation were less than 7% for all assays.   
Calculations.  Feed intake was calculated by subtracting unconsumed milk from 
the previous feed allowance.  Average daily gain (ADG) was calculated for each lamb as 
the slope of the regression of body weight over time.  Intake and weight gain relative to 
live weight (LW) were calculated by dividing daily intake and BW gain by the BW of the 
previous day.  Metabolic body weight (MBW) was calculated by scaling live body weight 
to the 0.58 power as suggested by Graham et al. (29) for neonatal lambs.  Empty body 
weight (EBW) is the sum of wet viscera and beheaded carcass weights.  Indices of 
fatness (mass of fat depots, visceral fat or carcass fat) were expressed as % of EBW.  
Composition of the EBW was calculated from the composition of viscera and carcass 
fraction.  
Data analysis.  All data were analyzed by ANOVA using SAS (SAS Institute, 
Raleigh, NC).  Data collected during the basal period were analyzed by a model 
accounting for body size at birth (BS, Normal vs. IUGR).  Averages were calculated for 
data collected over the treatment period (intake data, FWG, etc.).  Averages and end-
point data were analyzed by a model accounting for treatment (Normal, IUGR or IUGR-
MC4R).  When P-value was less than 0.15, the treatment effect was partitioned into 
contrasts accounting for the effect of BS (Normal vs. IUGR) and the effect of MC4R 
(IUGR vs. IUGR-MC4R).  With the exception of plasma variables, repeated measures 
data were analyzed by ANOVA using the MIXED procedure of SAS.  The model 
accounted for TRT, day and TRT by day as fixed effects and lamb as the random effect.  
In the case of plasma data, they were analyzed for each individual day by a model 
accounting for treatment as above.  
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To assess the possibility of intake-independent effects by the MC4R agonist, we 
conducted multiple regression analysis with data from treated and untreated IUGR 
lambs.  Effects of lipid intake and MC4R treatment on total lipid deposition, carcass lipid 
deposition and visceral lipid deposition were analyzed by ANOVA.  Statistical 
significance and tendency were set at P<0.05 and P<0.1 for main effects and P<0.1 and 
P<0.15 for interactions. 
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Results 
Growth and Intake.  Performance data collected between birth and initiation of 
treatment on day 4 are provided in Table 4.2.  IUGR lambs had lower absolute dry 
matter intake but tended to have higher relative dry matter intake (P<0.06).  Energy 
intake relative to live body weight was higher in IUGR than Normal lambs (P<0.04), but 
this difference disappeared when energy intake was expressed relative to MBW.  Total 
weight gain during the pretreatment period was not significantly different between IUGR 
and Normal lambs but ADG tended to be greater in Normal lambs (P<0.09).  IUGR 
lambs, however, had significantly higher FWG before treatment (P<0.02).  Normal lambs 
continued to be heavier than IUGR lambs on day 3, immediately before treatment 
(P<0.001). 
Intake and growth data for the treatment period are reported in Table 4.3. Normal 
lambs continued to outperform IUGR lambs in terms of dry matter and energy intake, 
average daily gain and total weight gain (Table 4.3; BS<0.04 or less).  The reciprocal 
was observed when dry matter intake, energy intake and growth rate were normalized to 
LW, with higher values seen in IUGR than Normal lambs (BS, P<0.05 or less).  Finally, 
IUGR and Normal lambs had similar energy intake normalized to MBW and identical 
CRL growth rates.  Overall, these data are in close agreement with the performance 
data we observed previously in Normal and IUGR lambs in early postnatal life (Chapter 
3).  
MC4R agonist administration to IUGR lambs caused a 25% reduction in dry 
matter and energy intake relative to their matched control when averaged over the entire 
period (MC4R, P<0.001).  As a consequence, relative dry matter and energy intake were 
less in IUGR-MC4R than in IUGR lambs (Table 4.3; MC4R, P<0.03), but numerically 
identical to those of Normal lambs.  These anorexic effects of the MC4R agonist were  
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Table  4.2  Effect of birth size on dry matter, nutrient intake and growth between birth and day 3 of postnatal life. 
Variablea 
Birth sizeb 
 
SD Probability levelc Normal  IUGR 
Dry matter intake      
Absolute, g/d 218  156 32 <0.003 
Relative to LW, g/kg  d 45  52 7 0.06 
Energy intake      
Absolute, kcal/d 1180.6  864.1 168.9 <0.004 
Relative to LW, kcal/kg  d 241.3  290.2 40.0 <0.04 
Relative to MBW, kcal/kg0.58 d 469.3  457.4 65.9 NS 
Growth      
Weight gain, kg 0.96  0.78 0.24 NS 
Weight on day 3, kg 5.2  3.2 0.5 <0.001 
ADG, kg/day 0.34  0.26 0.08 0.09 
FWG, %/day 7.0  9.7  1.8 <0.02 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain. 
bLambs were normal size (Normal, n = 5) or intrauterine growth-retarded (IUGR, n = 12). 
cType I error probability.  NS = P>0.10.
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Table  4.3  Effect of birth size and MC4R agonist on dry matter intake between day 4 and 15 of postnatal life. 
 Treatmentb   Probability levelc 
Variablea Normal  IUGR  IUGR-MC4R SD TRT BS MC4R  
Dry matter intake          
Absolute, g/d 340  275  207 24 <0.001 <0.001 <0.001 
Relative to LW, g/kg  d 46  53  46 5 <0.05 <0.04 <0.03 
Energy intake          
Absolute, kcal/d 1877.4  1513.6  1150.7 126.7 <0.001 <0.001 <0.001 
Relative to LW, kcal/kg  d 253.2  292.2  253.7 28.6 0.05 <0.05 <0.03 
Relative to MBW, kcal/kg0.58 d 595.8  584.2  479.8 46.7 <0.002 NS <0.002 
Growth          
Weight gain, kg 4.01  3.45  2.72 0.45 <0.001 <0.04 <0.01 
Final BW, kg 9.71  6.95  6.00 0.46 <0.001 <0.001 <0.003 
ADG, kg/day 0.37  0.31  0.25 0.03 <0.001 <0.01 <0.005 
FWG, %/day 5.1  6.4  5.5 0.8 0.05 <0.03 0.08 
CRL gain, cm/day 1.0  1.1  1.2 0.36 NS NS NS 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain; CRL, crown-rump 
length. 
bLambs were normal size (Normal) or intrauterine growth retarded (IUGR).  They were treated between day 4 and 15 of postnatal life 
with either excipient (Normal n = 5 and IUGR n = 6) or MC4R agonist (IUGR-MC4R, n = 6). 
cType I error probability for the effect of Treatment (TRT) and preplanned comparisons of birth size (BS, Normal vs. IUGR) and 
MC4R agonist therapy (MC4R, IUGR vs. IUGR-MC4R).  NS = P>0.10.
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seen on the very first day of treatment and sustained over the entire period of treatment 
(Fig. 4.1; MC4R, P<0.005). 
MC4R agonist treatment reduced energy intake corrected for MBW by ~18% 
(Table 4.3; MC4R, P<0.002).  As expected from the feed intake response, MC4R 
stimulation reduced average daily gain and weight gain by ~20% (MC4R, P<0.01 or less) 
and tended to reduce the FWG to that seen in Normal lambs.  The profile of BW 
suggests that effects of the MC4R agonist on growth were also constant over time (Fig. 
4.2).  MC4R agonist treatment had no effect on daily CRL gain. 
Body composition.  Body composition was analyzed after 12 days of treatment 
on day 15 of postnatal life.  The EBW was less for the IUGR than Normal lambs (Table 
4.4; BS, P<0.01).  BS had no effect on visceral and carcass fat (Fig. 4.3), the mass of 
the various visceral fat depots (Fig. 4.4) or percent fat in the EBW (Table 4.4) even 
though all indices were numerically higher in IUGR than Normal lambs.  In contrast, 
MC4R agonist treatment caused a 28% reduction in the fat content of the EBW (Table 
4.4; MC4R, P<0.002).  This reduction was apparent in the carcass (~27%) fraction of the 
EBW (Fig. 4.4; MC4R, P<0.001) and in all visceral fat depots with the exception of the 
perirenal depot (Fig. 4.4; MC4R, P<0.03 or less).  For the viscera fraction of the EBW, 
the overall TRT effect tended to be significant (Fig. 4.3, P = 0.10) and the MC4R effect 
was significant. 
De novo lipogenesis is almost non-existent in neonatal ruminants.  This is due to 
near total absence of the major source of carbon for fatty acid synthesis in milk-fed 
ruminants (i.e. acetate) and low ability to use glucose as an alternate substrate (30, 31).  
It follows that lipid intake is the major determinant of lipid accretion in neonatal ruminants 
(32).  To determine whether the anorexic effects of the MC4R agonist on fatness were  
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Figure  4.1  Effect of body size and MC4R agonist on voluntary dry matter intake. 
Lambs were Normal size (Normal) or intrauterine growth retarded (IUGR) at birth.  
Treatments started on day 4 of life and consisted of thrice daily injection of excipient 
(Normal, n = 5; IUGR, n = 6) or MC4R agonist (IUGR-MC4R, n = 6).  Voluntary intake 
was recorded daily.  The effect of Treatment (TRT) was significant at P<0.001 and was 
further analyzed by preplanned contrast accounting for the effect of body size (BS = 
Normal vs. IUGR) and MC4R agonist (MC4R = IUGR vs. IUGR-MC4R).  The P-values of 
these contrasts are given when significant.  The pooled SE was 17.7 for n = 6 and 19.4 
for n = 5.  
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Figure  4.2  Effect of birth size and MC4R agonist or excipient treatment on body 
weight. 
Lambs were Normal size (Normal) or intrauterine growth retarded (IUGR) at birth.  
Treatments started on day 4 of life and consisted of thrice daily injection of excipient 
(Normal, n = 5; IUGR, n = 6) or MC4R agonist (IUGR-MC4R, n = 6).  Body weights were 
recorded daily.  The significant effects of Treatment (TRT), Day and TRT x Day are 
reported.  The TRT x Day interaction was analyzed further by a first contrast accounting 
for the interaction between BS (BS = Normal vs. IUGR) and Day and a second contrast 
accounting for the interaction between MC4R agonist (IUGR vs. IUGR-MC4R) and Day. 
Neither of these contrasts was significant.  The pooled SE was 0.22 for n = 6 and 0.24 
for n = 5.   
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Table  4.4  Effect of birth size and MC4R agonist on body composition on day 15 of postnatal life. 
 Treatmentb  Probability levelc 
Variablea Normal  IUGR  IUGR-MC4R  SD TRT BS MC4R 
EBW, kg 8.07  5.90  4.91  0.36 <0.001 <0.001 <0.001 
Carcass (% EBW) 78.1  77.3  78.2  1.2 NS NS NS 
Viscera (% EBW) 21.9  22.7  21.8  1.2 NS NS NS 
           
Composition of EBW 
Water % 71.1  71.1  73.2  0.8 <0.001 NS <0.001 
Protein % 17.6  17.1  17.6  0.4 0.08 0.06 0.04 
Fat % 8.3  9.0  6.5  1.0 <0.003 NS <0.002 
Ash % 2.7  2.7  2.8  0.3 NS NS NS 
aEBW, empty body weight.  
bLambs were normal size (Normal) or intrauterine growth retarded (IUGR).  They were treated between day 4 and 15 of postnatal life 
with either excipient (Normal n = 5 and IUGR n = 6) or MC4R agonist (IUGR-MC4R, n = 6). 
cType I error probability for the effect of Treatment (TRT) and preplanned comparisons of birth size (BS, Normal vs. IUGR) and 
MC4R agonist therapy (MC4R, IUGR vs. IUGR-MC4R).  NS = P>0.10. 
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Lambs were Normal size (Normal) or intrauterine growth retarded (IUGR) at birth.  
Treatments started on day 4 of life and consisted of thrice daily injection of excipient 
(Normal, n = 5; IUGR, n = 6) or MC4R agonist (IUGR-MC4R, n = 6).  Each bar 
represents the mean ± SE of 5-6 lambs.  The treatment effect tended towards 
significance for the viscera fraction (P = 0.10) and was significant for carcass (P<0.001).  
These effects were further analyzed by contrasts accounting for the effect of body size 
(BS, Normal vs. IUGR) and MC4R agonist (MC4R, IUGR vs. IUGR-MC4R).  The P-
values of these contrasts are given when significant.  
Figure  4.3  Effect of birth size and MC4R agonist on the fat content of the carcass 
and viscera. 
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Lambs were Normal size (Normal) or intrauterine growth retarded (IUGR) at birth.  Treatments started on day 4 of life and consisted 
of thrice daily injection of excipient (Normal, n = 5; IUGR, n = 6) or MC4R agonist (IUGR-MC4R, n = 6).  Fat depots were dissected, 
weighed, and expressed as a % of empty body weight (EBW).  When P-value for treatment was less than 0.15, it was further 
analyzed by preplanned contrasts of body size (BS, Normal vs. IUGR) and MC4R agonist (MC4R, IUGR vs. IUGR-MC4R).  The P-
values of these of the contrasts are given when significant.   
MC4R, P <0.03 MC4R, P <0.007 
MC4R, P <0.02 MC4R, P <0.02 
Figure  4.4  Effect of birth size and MC4R agonist on the mass of visceral fat depots. 
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accounted entirely by its anorectic effect, the relation between lipid deposition in the 
EBW and lipid intake was determined by regression analysis.  Lipid intake accounted for 
90% of the variation in lipid deposition (P<0.001).  However, an additional 4% was 
accounted by a model including MC4R treatment (P<0.04).  When the same analysis 
was performed separately for lipid deposition in the carcass and in the viscera, the 
MC4R effects was present only in the carcass, explaining an additional 7% of the 
observed variation (r2= 0.88 vs. 0.95; P<0.007).  This suggests that MC4R agonist 
reduces lipid accretion by both intake and intake-independent mechanisms, with the 
latter occurring predominantly in the carcass.  
Metabolic indices.  Blood samples were obtained the day before treatment on 
day 3 of postnatal life and analyzed for the plasma concentration of glucose and 
selected metabolic hormones (Table 4.5).  BS did not affect plasma variables with the 
exception that IUGR lambs had significantly lower plasma T4 (P<0.003) and tended to 
have lower plasma IGF-1. 
These analyses were repeated on day 2, 4 and 10 of treatment except for 
plasma insulin (Fig. 4.5).  Results are reported as absolute values for variables that did 
not differ before treatment (glucose and leptin) and as changes from pretreatment values 
for those that differed on day 3 (IGF-1 and T4).  BS had no effect on plasma glucose, 
leptin or on the increase in plasma IGF-1 and T4 at any time point during the treatment 
period.  Similarly, MC4R agonist treatment did not have a significant effect on plasma 
leptin or on the increase in plasma IGF-1.  MC4R agonist treatment significantly reduced 
plasma glucose on day 2 of treatment, but this effect disappeared thereafter.  The 
increase in T4 was significantly greater in MC4R agonist treated lambs on day 4 and 
tended to be greater on day 10 of treatment (Fig. 4.5). 
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Table  4.5  Effect of birth size on glucose and hormones concentration on day 3 of postnatal life. 
 Birth sizea    
Variable Normal  IUGR  SD Probability levelb 
Glucose, mg/dl 131  124  17 NS 
Insulin, ng/ml 2.2  1.5  1.4 NS 
IGF-1, ng/ml 239  187  48 <0.07 
Leptin, ng/ml 3.9  3.8  0.8 NS 
Total T4, nmol/l 105  73  16 <0.003 
aLambs were normal size (Normal, n = 5) or intrauterine growth-retarded (IUGR, n = 12). 
bType I error probability.  NS = P>0.10. 
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Lambs were Normal size (Normal) or intrauterine growth retarded (IUGR) at birth.  Treatments 
started on day 4 of life and consisted of thrice daily injection of excipient (Normal, n = 5; IUGR, n 
= 6) or MC4R agonist (IUGR-MC4R, n = 6).  Blood was obtained at 1600 h on day 2, 4 or 10 of 
treatment.  When P-value of treatment (TRT) was less than 0.15 effects were further analyzed by 
contrast accounting for the effect of body size (BS = Normal vs. IUGR) and MC4R agonist (MC4R 
= IUGR vs. IUGR-MC4R).  
Figure  4.5  Effect of birth size and MC4R agonist on the plasma concentration of 
glucose and selected hormones. 
TRT,  P=0.06 
MC4R, P<0.003 
MC4R, P=0.10 
MC4R,P<0.03 
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Discussion 
The IUGR condition is frequently associated with accelerated growth or ‘catch-up’ 
growth soon after birth (33–35).  Epidemiological studies have also revealed positive 
associations between early catch-up growth and higher indices of adiposity in pre-
adolescent children (36–38).  Similar results have been obtained in both rodent and 
ovine IUGR models.  In rodents, numerous experiments show that the IUGR condition 
has long-term consequences on energy metabolism, such as increased appetite, lower 
energy expenditure and overall adiposity (18, 39, 40).  Our own work with the multifoetal 
IUGR sheep model confirmed the positive association between accelerated growth and 
fatness as early as day 14 of postnatal life (chapter 3).  Considering that obesity is linked 
to insulin and leptin resistance, early obesity could be a self-amplifying phenomenon that 
progressively increases the risk of metabolic syndrome during postnatal life.  Therefore, 
it is crucial to understand which energy homeostatic systems operate in early postnatal 
life so that strategies can be developed to address increased lipid deposition of IUGR 
individuals in early life. 
The central nervous is regarded as the most important regulator of energy 
homeostasis in postnatal life. However, the ability of this system to respond to leptin and 
other peripheral cues is limited in neonatal rodents (41, 42).  Moreover, the therapeutic 
value of leptin appears limited in normoleptinemic humans (43, 44).  In this context, 
targeting signals operating downstream of leptin, such as the MC system is attractive.  
The crucial role of this system is supported by the decreased energy expenditure and 
increased appetite and fatness of mice (45–47) and humans (48–50) harboring null 
mutations in the genes associated this system. 
With this in mind, MC analogues have been designed to incorporate two major 
features (51, 52).  First, they must preferably target the MC4R.  While endogenous MC 
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can activate any of the 5 MC receptors, the MC4R is found almost exclusively in the 
central nervous system and is by far the most important MC receptor regulating energy 
metabolism (53).  Second, any peripherally administered MC4R analogue must cross 
the blood-brain barrier to act.  BIM-22493 is a MC agonist that incorporates both of these 
features.  For instance, it has a ~5 fold higher affinity and 20 times lower EC50 for MC4R 
over MC3R, the other major MC receptor present in the brain (54).  Moreover, BIM-
22493 has no actions in MC4R knockout mice but retains efficacy in MC3R knockout 
mice (54).  So far, natural MC and chemical agonists, such as BIM-22493, have been 
tested only in adult animals (54, 55).  In the case of BIM-22493, these experiments 
demonstrated that a dose of 300 and 447 nmol/kg/day reduced voluntary intake and 
weight in mice and rhesus macaques (54, 56) .  Using a dose of 450 nmol/kg/day, we 
were able to induce similar effects as early as 4 days of life in neonatal sheep.  The 
reduction in intake observed in rodents and rhesus macaques initially reached 20 to 35% 
but dissipated completely after 12 days in mice and 4 weeks in monkeys (54, 56).  
Tachyphylaxis has been a recurrent observation with the use of artificial or natural MCR 
agonists in rodents and non-human primates (56–59).  This did not seem to be the case 
in our experiment as feed intake was reduced by 25% in IUGR neonatal lambs 
throughout the 12-day experimental period.  As we previously reported IUGR lambs 
have elevated relative feed intake in early life.  Accordingly, it is interesting to see that 
MC4R agonist treatment completely corrected this elevation. 
Hypothalamic stimulation with either BIM-22493 or other MC4R agonists is 
associated with consistent weight loss in adult animals (54, 56–58, 60).  These weight 
reductions were explained by the loss fat and lean in rodents and non-human primates 
(56–58).  In growing animals, it is known that a reduction in feed intake causes reduced 
fat content in the EBW.  For example, Greenwood et al. (1) compared body composition 
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in neonatal IUGR lambs fed to grow at 150 g/d or fed unlimited amounts and growing at 
239 g/d.  At the same EBW of 4.9 kg, restricted lambs had 23% lower fat content but 
similar rate of retention for protein and ash.  Our data shows that the 25% feed intake 
reduction seen with BIM-22493 was associated with reductions of 21% for BW growth, 
28% for fat content in the EBW and 25% for the mass of visceral fat depots.  Previous 
data indicate that reduction in body weight and fatness induced by melanocortin 
stimulation is mostly explained by lower voluntary intake (58).  However, pair-fed studies 
have revealed that a portion of the MC agonist effect is intake-independent and likely 
accounted by stimulation of basal metabolic rate (56–58, 60).  Unfortunately, we were 
not able to include a pair-fed group to MC4R treated animals due to a lack of IUGR 
lambs. 
As an alternative step to ask if MC has intake-independent effects on fat 
deposition, we examined the relation between lipid intake and lipid deposition in treated 
and untreated IUGR animals given that accreted lipids in milk-fed ruminants originate 
nearly exclusively from dietary lipids (30, 31).  This analysis suggests that MC evoked an 
additional mechanism to reduce lipid accretion operating predominantly in the carcass 
fraction.  In agreement with these data, mice and rats treated with MC agonist had lower 
subcutaneous fat but similar visceral fat than pair-fed controls (57). Previous 
experiments in MC-treated rodents and humans, indicate that MCR agonists increase 
lipolysis (deduced from glycerol release and gene expression data) and fatty acid 
oxidation  (deduced from changes in respiratory quotient) (20, 54, 60, 61).  A second 
related mechanism for an intake-independent effect could be increased T4 production.  
In our experiment, MC4R agonist caused an increase in plasma T4 that was sustained 
for most of the experimental period.  It is now known that ARC-derived α-MSH activates 
MC4R in TRH-neurons located in the PVN, ultimately stimulating T4 production (62).  
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Thyroid hormones increase energy expenditure by increasing uncoupling proteins in 
brown adipose tissue and muscle (63, 64), leading to substrate flux in the TCA cycle 
without increasing ATP production (65).  Interestingly, in a previous experiment we 
showed that neonatal IUGR lambs have lower circulating T4 concentration than normal 
lambs and that this reduction is associated with higher body fatness (Chapter 3).  It has 
been recently demonstrated that T3 can suppress the expression of MC4R in the PVN, 
providing a negative feedback mechanism to protect from inappropriate melanocortin 
stimulation (66).  This may explain the tachyphylaxis observed previously in adult 
rodents and rhesus macaques treated chronically with a MC4R agonist (54, 56).  We did 
not observe any loss of MC effectiveness in our experiment, raising the possibility that 
this mechanism does not operate in early life or in this species. 
MC4R deficiency in humans is associated with increased linear growth that starts 
in early childhood (67, 68).  Martinelli et al. (67) offered a possible explanation for the 
phenomenon.  They observed that mean growth hormone concentration is greater in 
MC4R deficient patients than in controls matched for the same level of fatness.  
Surprisingly, the concentration of IGF hormones and their binding proteins was not 
affected by MC4R deficiency.  Work with rats supported this observations by 
demonstrating that direct stimulation of hypothalamic melanocortin receptors in rats did 
not decrease circulating IGF-1 concentration beyond the level observed in pair-fed 
controls (69).  In our experiment, BIM-22493 appeared to halt the normal increase in 
IGF-1 observed in the untreated IUGR lambs on day 4 but changes were not significant.  
Likely, as observed in rodents, this is a reflection of the lower plane of nutrition 
experienced by MC4R-treated animals.  Finally, MC4R did not impact linear growth 
during our 11-day experimental period.  
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In mice, MC treatment causes acute increases in glucose uptake, skeletal and 
cardiac muscle and in BAT (70, 71). Chronic MC therapy of rodents and rhesus 
macaques improved various indices of insulin action (improved glucose clearance 
combined with lower insulin secretion), particularly in animals exposed to high fat diets 
(56).  These favorable effects on insulin action likely relate to reduced fatness in these 
treated adult animals (54, 56).  In the present work, blood was collected under free-
feeding conditions, making it difficult to assess MC4R agonist effect on insulin action.  
Finally, we were not able to detect differences in circulating leptin with BIM-22593 
treatment.  This is not completely surprising as we have previously shown that plasma 
leptin does not dynamically respond to plane of nutrition in early life (28). 
In summary, chronic treatment with MC4R agonist reduced voluntary intake, 
normalized fractional growth rates and reduced carcass and visceral adiposity.  These 
reductions in fatness induced by MC4R agonist are likely explained by lower nutrient 
intake as well as by other effects such as increased metabolic rate.  Finally our data 
shows that MC4R signaling operates immediately after birth and could be harnessed to 
combat the excessive fatness observed in IUGR individuals.  
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CHAPTER  5 :  ACUTE AND LONG-TERM EFFECTS OF EARLY LEPTIN 
ANTAGONIST TREATMENT ON INTAKE, GROWTH AND BODY 
COMPOSITION OF NEONATAL LAMBS. 
 
Introduction 
Based on epidemiological studies, David Barker and Osmond (1) suggested in 
the mid 1980’s that the health of the adult could be influenced by pre-natal events.  This 
group observed that women born to mothers that suffered the Dutch famine of 1944-45 
during early pregnancy were lighter at birth but had higher BMI at age 50 than those 
born to non-exposed women (2).  Additionally, retrospective epidemiological studies of 
twins uncovered negative non-genetic effects of low birth weight on fatness and glucose 
metabolism of young and elderly individuals (3, 4).  Since then, researchers have 
continued to explore the consequences of intra-uterine growth retardation (IUGR) using 
animal models.  For instance, several experiments with rodents have shown that IUGR 
pups develop higher intake, body weight gain and adiposity either when nursed by 
mothers fed ad libitum or are offered high fat diets during the post-weaning period (5–9).  
The hypothalamus plays a central role in the regulation of energy metabolism 
(10).  A simplified model of hypothalamic function proposes that first order neurons 
located in the arcuate nucleus play a predominant role in assessing the overall energy 
condition via peripheral cues such as leptin, insulin and glucose (11).  These sensory 
neurons are connected to second order neurons located in other hypothalamic nuclei via 
a network of axonal projections.  Secondary neurons are responsible for initiating 
appropriate responses, including regulation of intake, energy expenditure and 
metabolism. In rodents, fetal insults including the IUGR condition impacts the 
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development of this hypothalamic network (12).  Bouret et al. (13) demonstrated that this 
network was nearly inexistent in ob/ob pups.  They demonstrated that leptin therapy 
between day 4 and 12 of postnatal life normalizes the axonal density of this system in 
ob/ob mice and partially rescues the hyperphagia observed in these mice.  These 
observations led to the hypothesis that defective development of this network could 
mediate the detrimental effects of inadequate nutrition in fetal and early postnatal life 
(14). In fact, Vickers et al. (5) demonstrated that leptin therapy between day 3 and 13 of 
postnatal life eliminated this propensity to develop obesity and hyperphagia in later life. 
Hypothalamic development in rodents however, is temporally distinct from 
precocial animals such as primates, humans and sheep (15–19).  This hypothalamic 
network system is believed to be substantially more developed at birth in these precocial 
species, even though some additional maturation occurs after birth (18).  However, it is 
not known if leptin is capable of regulating appetite during early life or if its early 
signaling has long-term consequences on metabolism, body composition or appetite in 
precocial animals.  To address this question we treated newborn lambs with a leptin 
receptor antagonist (20) during the first 14 days of life and evaluated effects of this 
treatment on appetite and body composition until day 40 of life.  We also evaluated 
effects of this antagonist in 1-month old lambs. 
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Materials and Methods 
Animals and study design.  All experimental procedures were approved by the 
Cornell University Institutional Animal Care and Use Committee.  Male lambs from Finn 
X Dorset genotype parents were obtained from the Cornell Teaching and Research. 
Twenty lambs were obtained at birth, towel-dried, weighed and bottle-fed a single 
dose of 10% of body weight of a common pool of bovine colostrum.  Animals were 
transported immediately to the Cornell University Large Animal Research and Teaching 
Unit and housed in individual cages (75 cm width x 80 cm length x 80 cm height) at 
constant temperature (25° to 27 °C) and photoperiod (light on between 0700 and 1900 
h).  Immediately after birth, animals were randomly allocated to 3 treatment groups. 1) 
Control: lambs received twice daily intravenous (IV) injection of saline from birth until day 
14 of postnatal life, and again between day 30 and 35 of life (n = 6); 2) Early super ovine 
leptin antagonist (SOLA): lambs received twice daily IV injection of SOLA from birth to 
day 14 of life (total daily dose = 0.46 mg/kg0.75) followed by twice daily IV injection of 
saline between day 30 and 35 of life (n = 6); 3) Late SOLA: lambs received twice daily IV 
injection of saline between birth and day 14 of life followed by twice daily IV injection of 
SOLA from day 30 to 35 of life (total daily dose = 0.91 mg/ kg0.75) (n = 8).  For all 
treatments, the twice daily IV injections were performed at 0800 and 2000 h. 
SOLA was obtained from PLR Ltd. (Rehovot, Israel).  SOLA is a mutant ovine 
leptin in which amino acid 23 (aspartic acid) is replaced by leucine and amino acids 39 
to 41 (leucine-aspartic acid-phenylalanine) have been replaced by alanine (21).  This 
mutant leptin has higher affinity for leptin receptors than wild type ovine leptin, but it is 
completely unable to activate signaling.  In addition, a polyethylene glycol molecule was 
attached to SOLA to prolong its half-life (20, 22). 
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Experimental procedures were as follows.  Lambs received unlimited amounts of 
a commercial milk replacer (Milk Specialties Global, Carpentersville, IL; Table 5.1). Milk 
replacer was reconstituted with water at 18.8% dry matter and served at 0900 h.  The 
milk replacer was replenished if needed at 1600 and 2000 h.  Offered volume was 
incrementally adjusted on daily basis.  Body weight (BW) was recorded daily at 1600 h.  
Blood samples were obtained by jugular venipuncture within 2 h of birth.  Thereafter, 
blood samples were obtained at 1600 h on postnatal day 1, every other day between 
day 2 to 20 and daily between day 28 to 35.  Blood samples were collected in 6-ml tubes 
containing 90 USP lithium heparin.  Plasma was prepared by centrifugation and stored 
at -20°C until analyzed for glucose and selected hormones. 
Tissue collection and body composition.  All lambs were killed on day 40 of 
postnatal life by IM injection of Xylazine (55 μl/kg LW, AnaSed, Lloyd Inc. IA) followed by 
IV injection of Propofol (4 mg/kg LW, PropoFlo, Abbott Laboratories, IL).  The head was 
severed immediately between the cranium and the first cervical vertebrae and processed 
for isolation of the hypothalamus.  Blood was collected and weighed.  The 
gastrointestinal (GI) tract was dissected and weighed before and after contents were 
removed.  Omental, perirenal, retroperitoneal and pericardial fat depots were dissected 
and weighed separately.  The viscera fraction was obtained by combining GI tract, blood, 
visceral fat depots and visceral organs (respiratory tract, heart, liver and spleen) 
whereas the carcass fraction consisted of the carcass (without the head), skin and hoofs. 
Each fraction was grounded separately by extrusion through grinding plates (Viscera: 2x 
through a 13-mm plate and 3x through a 4-mm plate; Carcass: 1x through a 50-mm 
kidney plate, 3x through a 13-mm plate and 3x through a 4-mm plate).  A 250 g 
subsample of each fraction was freeze-dried for determination of dry matter.  The freeze-
dried samples were then pulverized with dry ice using a Waring blender and stored at  
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Table  5.1  Nutrient composition of milk replacer.. 
 
 
 
 
 
 
 
 
 
 
 
Nutrient -- per kg dry matter -- 
Gross energy, Mcal 5.87 
Crude protein, g 253 
Fat, g 302 
Nitrogen free extract, g 363 
Ash, g 81 
Vitamin A, KIU 44.0 
Vitamin D3, KIU 11.0 
Vitamin E, IU 330 
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-20°C until analyzed for nitrogen, ether extract and ash content.  Nitrogen (N) content 
was measured by macro-Kjeldahl digestion (23) with steam distillation into boric acid 
using a Kjeltec 2300 (FOSS Analytical AB, Sweden).  Crude protein was calculated as N 
x 6.25.  Fat content of body fractions was determined by petroleum-ether extraction (24).  
Ash content was determined by incinerating samples in a furnace at 506 °C for 16 h.  All 
samples were analyzed in duplicate.  Milk replacers were analyzed similarly except that 
a factor of 6.38 was applied to N content to calculate CP and fat content was measured 
by an hexane/isopropanol extraction (25). 
Glucose and hormones analyses.  Plasma glucose was measured by the glucose 
oxidase method (510A; Sigma Chemical, St. Louis, MO) (26).  Total plasma thyroxine 
(T4) was measured using a commercial solid-phase RIA (Coat-a-Count, Siemens, 
Germany) previously validated in the sheep (27).  Internal RIA previously validated with 
ovine plasma were used to measure the plasma concentration of insulin, IGF-1 and 
leptin.  These RIA use bovine proteins for iodination and standards.  The insulin RIA was 
performed with a guinea pig anti-bovine insulin primary antibody (Sigma I-6136) and a 
goat anti-guinea pig secondary antibody (Equitech-Bio Inc., Kerrville, TX) (28). For IGF-1, 
IGF-binding proteins were first removed by acid-ethanol extraction.  Supernatant was 
then analyzed using an IGF-1 assay based on a rabbit anti-human IGF-1 primary 
antibody (lot AFP4892898; National Hormone and Peptide Program) and a caprine anti-
rabbit γ-antibody (lot 12515; Biotech Source Inc.) (26).  Leptin was analyzed with a 
bovine leptin RIA previously validated in sheep (28).  The same assay was used for 
samples obtained during SOLA treatment, except that SOLA was used to generate the 
standard curve.  Inter- and intra-assay coefficients of variation were less than 12% for 
the SOLA leptin assay and less than 7% for all other assays.   
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Calculations.  Daily feed intake was calculated by subtracting unconsumed milk 
replacer from the previous feed allowance.  Average daily gain (ADG) was calculated for 
each individual as the slope of the regression of body weight over time.  Relative intake 
and fractional weight gain were calculated by dividing daily intake or BW gain by the BW 
of the previous day.  Metabolic body weight (MBW) was calculated by scaling live body 
weight to the 0.58 power based on studies showing that this exponent relates more 
closely to basal energy expenditure in neonatal lambs than the commonly used 0.75 (29).  
Empty body weight (EBW) is the sum of wet viscera and beheaded carcass weights.  
Indices of fatness (mass of fat depots, visceral fat or carcass fat) were expressed as % 
of EBW.  Composition of the EBW was calculated from the composition of viscera and 
carcass fraction. 
Statistical analyses.  All data were analyzed by ANOVA.   
Effects of Early and Late SOLA treatment were analyzed separately.  For Early 
SOLA, averages were calculated for intake and growth data (e.g. intake, FWG, etc.) for 
both the treatment period (day 1 to 14) and post-treatment period (day 15 to 39).  These 
data were analyzed separately with a model accounting for SOLA effects (saline vs. 
SOLA).  Repeated measures data (e.g. intake, body weight, plasma variables) were 
analyzed with the MIXED procedure of SAS using a model accounting for SOLA 
treatment, day and their interaction as fixed effects and animal as the random effect. 
For the Late SOLA, the treatment period was day 30 to 35 and the post-
treatment period was day 36 to 39.  Procedures and models used were the same as for 
the Early SOLA analysis except for the following: pre-treatment body weight (average of 
day 25 to 29) was included as a covariate for any intake or growth variables not already 
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normalized by body weight.  Statistical significance and tendencies were set at P<0.05 
and P<0.15 for main effects and P<0.10 and P<0.15 for interactions. 
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Results 
 
Effect of leptin antagonist therapy from birth to day 14 of post-natal life.  
Intake and Growth. Treatments were initiated before any colostrum or milk was 
provided.  Both groups weighed exactly the same at birth (Table 5.2).  Leptin antagonist 
therapy tended to cause a 26% increase in absolute dry matter and energy intake when 
averaged over the entire experimental period (P = 0.12).  The same effects were 
observed even when intake of dry matter and energy were expressed relative to body 
weight or MBW (P = 0.10).  Examination of the daily profile shows that tendency of 
SOLA treatment to increase intake variables was seen throughout the treatment period 
(Fig. 5.1 and 5.2, treatment period, SOLA, P = 0.13 or less). 
Consistent with intake data, SOLA treated lambs showed greater absolute 
average daily gain and fractional weight gain (Table 5.2, P<0.04 or less).  In agreement 
with this effect, SOLA treatment increased total body weight gain (Table 5.2, P<0.07) 
and the profile of body weight over time (Fig. 5.3, treatment period, SOLA x Day, 
P<0.03).  SOLA treatment had no effect on the rate of linear growth expressed as CRL 
gain (Table 5.2). 
Next, carry-over effects of early SOLA therapy were assessed between day 15 to 
39 of postnatal life.  When averaged over this period, all intake and growth parameters 
were identical between Control and SOLA groups, including body weight on day 39 
(Table 5.3).  In agreement with these data, Control and SOLA treated lambs had an 
overlapping profile of absolute intake and relative dry matter intake over this period of 
time (post-treatment period, Fig. 5.1 and 5.2).  Moreover, profiles of body weight over 
time became parallel (post-treatment period, Fig. 5.3).  
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Table  5.2  Effect of early leptin antagonist therapy on intake and growth during the treatment period (birth to day 14 of 
postnatal life). 
 Treatmentb   
Variablea Control SOLA SE Probability levelc 
Dry matter intake     
Absolute, g/d 193 244 22 0.12 
Relative to LW, g/kg  d 37 43 2 0.10 
Energy intake     
Absolute, kcal/d 1131.3 1433.6 127.2 0.12 
Relative to LW, kcal/kg  d 218.9 254.0 13.5 0.10 
Relative to MBW, kcal/kg0.58 d 433.8 521.6 34.1 0.10 
Growth     
Birth weight, kg 3.61 3.64 0.21 NS 
Weight gain, kg 3.05 3.95 0.32 0.07 
Weight on day 15, kg 6.66 7.59 1.08 NS 
ADG, kg/day 0.19 0.26 0.02 <0.03 
FWG, %/day 4.2 5.2 0.3 <0.04 
CRL gain, cm/day 0.6 0.6 0.1 NS 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain; CRL, crown-rump 
length. 
bLambs were treated between birth (before first feeding) and day 14 of postnatal life with either excipient (Control, n = 6) or leptin 
antagonist (SOLA, n = 6). 
cType I error probability for the effect of leptin antagonist .  NS = P>0.15. 
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Figure  5.1  Effect of leptin antagonist therapy on voluntary dry matter intake in 
early postnatal life. 
Lambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6).  Treatment and post-
treatment periods were analyzed separately. The P-values are given only for effects that 
were significant (P<0.05) or tended to be significant (P<0.15). The pooled SE during the 
treatment period was 26 and 34 during the post-treatment period. 
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Figure  5.2  Effect of leptin antagonist therapy on relative dry matter intake in early 
postnatal life. 
Lambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6).  Treatment and post-
treatment periods were analyzed separately. The P-values are given only for effects that 
were significant (P<0.05) or tended to be significant (P<0.15). The pooled SE during the 
treatment period was 3.8 and 2.6 during the post-treatment period. 
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Figure  5.3  Effect of leptin antagonist therapy on body weight in early postnatal 
life. 
Lambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6).  Treatment and post-
treatment periods were analyzed separately. The P-values are given only for effects that 
were significant (P<0.05) or tended to be significant (P<0.15). The pooled SE during the 
treatment period was 0.35 and 0.70 during the post-treatment period. 
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Table  5.3  Effect of early leptin antagonist therapy on intake and growth during the post-treatment period (day 15 to 39 of 
postnatal life). 
 Treatmentb   
Variablea Control SOLA SE Probability levelc 
Dry matter intake     
Absolute, g/d 343 357 24 NS 
Relative to LW, g/kg  d 35 33 1 NS 
Energy intake     
Absolute, kcal/d 2012.4 2097.6 143.3 NS 
Relative to LW, kcal/kg  d 205.6 192.9 6.3 NS 
Relative to MBW, kcal/kg0.58 d 531.6 520.9 21.9 NS 
Growth     
Weight gain, kg 7.19 7.55 0.46 NS 
Weight on day 39, kg 13.85 15.14 0.85 NS 
ADG, kg/day 0.30 0.32 0.02 NS 
FWG, %/day 3.2 3.0 0.1 0.14 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain. 
bLambs were treated between birth (before first feeding) and day 14 of postnatal life with either excipient (Control, n = 6) or leptin 
antagonist (SOLA, n = 6). 
cType I error probability for the effect of leptin antagonist.  NS = P>0.15. 
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Finally, body composition was analyzed on day 40 of postnatal life, 26 days after 
the end of treatment (Table 5.4).  Leptin antagonist therapy during the first 14 days of 
post-natal life did not have any effect on empty body weight, its composition or 
distribution in viscera and carcass fractions at day 40.  Also, fatness assessed in 
carcass, viscera or EBW did not differ between treatments.  SOLA treatment had no 
effect on the mass of visceral fat depots considered individually or as a group.  
Plasma variables.  The concentration of plasma SOLA was measured every 2 
days during treatment and over the first 6 days post-treatment.  All samples were 
obtained 8-9 hours after the first IV injection.  Plasma SOLA rose rapidly to reach a near 
steady concentration of 970 ng/ml by day 4 of treatment (Fig. 5.4).  Over the same 
period, plasma leptin in Control animals averaged 4.2 ng/ml and was nearly constant 
(Fig. 5.4).  Accordingly, plasma SOLA excess over the endogenous plasma leptin 
concentration during the treatment period was 237-fold.  As expected, plasma SOLA 
dropped after treatment, reaching 175 ng/ml 56 h after last injection, and 20 ng/ml after 
another 56 h.  SOLA treatment had no effect on the concentration of plasma glucose, 
insulin or T4 when averaged over the treatment period (day 1 to 14, Table 5.5).  SOLA 
treatment was also devoid of effect over time on these variables with the single 
exception of glucose:  SOLA caused on elevation in plasma glucose over the first 2 day 
of treatment (Fig. 5.5; SOLA x Day, P<0.03) but failed to have the same effect on 
plasma insulin (Fig. 5.6). 
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Table  5.4  Effect of early leptin antagonist therapy on body composition on day 40. 
 Treatmentb  Probability 
level Variablea Control SOLA SE 
EBW, kg 11.5 12.7 0.8 NS 
     
Carcass      
Fraction of EBW (%) 80.9 80.1 0.8 NS 
Fat (% EBW) 13.8 14.2 1.0 NS 
     
Viscera      
Fraction of EBW (%) 19.1 19.9 0.8 NS 
Fat (% EBW) 4.1 4.3 0.5 NS 
     
Visceral fat depot (% of EBW)     
Perirenal 1.0 1.1 0.2 NS 
Omental 1.7 2.0 0.2 NS 
Retroperitoneal  1.4 1.4 0.2 NS 
Pericardial 0.3 0.3 0.1 NS 
All depots 4.4 4.8 0.6 NS 
     
Composition (% of EBW) 
Water 62.9 62.6 1.4 NS 
Protein 15.4 15.0 0.2 NS 
Fat 17.9 18.5 1.4 NS 
Ash 2.9 2.8 0.1 NS 
aEBW, empty body weight.  
bLambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6). 
cType I error probability for the effect of leptin super antagonist.  NS = P>0.15. 
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Figure  5.4  Concentration of endogenous plasma leptin or leptin antagonist during 
treatment. 
Lambs were treated from birth (before first feeding) until day 14 of postnatal life with 
twice daily injection of either excipient (Control, n = 6) or leptin antagonist (SOLA, n=6). 
Blood samples were obtained in the indicated days at 1600 h, 8 hours after the first daily 
IV injection.  Arrow indicates the last day of treatment.  Plasma SOLA was measured 
only in SOLA-treated lambs (top panel), and endogenous plasma leptin was measured 
only in control animals (bottom panel).  The pooled SE was 241 for SOLA and 0.4 for 
leptin. 
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Table  5.5  Effect of leptin antagonist therapy on the plasma concentration of 
glucose and selected hormones during treatment period (birth to day 14 of 
postnatal life). 
 Treatmenta  Probability 
levelb Variable Control SOLA SD 
Glucose, mg/dl  101 105 8 NS 
Insulin, ng/ml 1.9 2.2 1.8 NS 
Total T4, nmol/l 94 105 17 NS 
Leptin, ng/ml 4.2 ---- 0.3 ---- 
SOLA, ng/ml  ---- 985 165 ---- 
aLambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n=6) or leptin antagonist (PEGSOLA, n=6). 
bType I error probability.  NS = P>0.15. 
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Figure  5.5  Effect of leptin antagonist therapy on plasma glucose in early postnatal 
life. 
Lambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6).  Blood samples were 
obtained in the indicated days at 1600 h, 8 h after the first daily IV injection.  Treatment 
and post-treatment periods were analyzed separately. The P-values are given only for 
effects that were significant (P<0.05) or tended to be significant (P<0.15). The pooled SE 
during the treatment period was 5.7.  
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Lambs were treated between birth (before first feeding) and day 14 of postnatal life with 
either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 6).  Blood samples were 
obtained in the indicated days at 1600 h, 8 h after the first daily IV injection.  Treatment 
and post-treatment periods were analyzed separately. The P-values are given only for 
effects that were significant (P<0.05) or tended to be significant (P<0.15). The pooled SE 
during the treatment period was 1.8.  
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life. 
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Effect of leptin antagonist therapy from day 30 to 35 of postnatal life.  
Intake and Growth.  A second group of lambs received twice daily IV injection of 
SOLA between day 30 and 35 of postnatal age, and were compared to the original 
Control group injected with saline solution.  This second group of SOLA-treated lambs 
tended to be heavier than Control lambs at birth (Control vs. Late SOLA, 3.6 vs. 4.0 kg, 
P=0.12), and significantly heavier at both day 15 (6.7 vs. 8.0 kg, P<0.02) and before 
treatment on day 29 (10.4 vs. 12.6, P<0.01).  These differences occurred even though 
they were subjected to the same exact experimental procedures as the original Control 
group, including twice daily IV saline injection between birth and day 14.  Accordingly the 
pre-treatment body weight (average of day 25 to 29) was used as a covariate for the 
analysis of treatment and post-treatment effects on weight dependent variables (intake, 
ADG and BW). 
During treatment, SOLA had no effect on DM or energy intake variables 
averaged over the treatment period (Table 5.6) or analyzed over time (Fig. 5.7 and 5.8).  
This lack of effect was also seen for all growth variables (Table 5.6 and Fig. 5.9), except 
for the profile of body weight over time:  SOLA-treated lambs showed a steeper increase 
in BW during the treatment period (Fig. 5.10, SOLA x Day, treatment period, P<0.05). 
Performance was also measured for 5 days after last injection (day 36 to 39 of 
postnatal age).  Dry matter intake was numerically lower for SOLA than control animals 
and tended towards statistical significance when corrected for LW (Table 5.7, P = 0.11).  
The profiles over time suggest that these effects were initiated at cessation of treatment 
and remained constant over the entire post-treatment period (Fig. 5.7 and 5.8).  In 
particular, the carryover effect of SOLA on relative dry matter intake was significant 
when analyzed over time (Fig. 5.8, post-treatment, SOLA, P = 0.05).  Consistent with 
carryover effects of SOLA on intake variables, FWG was lower for SOLA lambs when 
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Table  5.6  Effect of leptin antagonist therapy on intake and growth during the treatment period (day 30 to 35 of postnatal 
life). 
 Treatmentc  
Probability leveld Variablea  Control SOLA SD 
Dry matter intake     
Absoluteb, g/d 442 431 59 NS 
Relative to LW, g/kg  d 34 33 3 NS 
Energy intake     
Absoluteb, kcal/d 2591.7 2527.8 344.3 NS 
Relative to LW, kcal/kg  d 199.0 195.1 17.6 NS 
Relative to MBW, kcal/kg0.58 d 553.9 592.1 66.8 NS 
Growth     
Weight on day 29, kg 10.36 12.58 1.28 <0.008 
Weight gainb, kg 2.76 2.84 0.60 NS 
Weight on day 36b, kg 14.35 14.49 0.66 NS 
ADGb, kg/day 0.34 0.43 0.11 NS 
FWG, %/day 3.1 3.2 0.5 NS 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain. 
bAdjusted by covariate analysis for pre-treatment body weight. 
c cLambs were treated from day 30 to 35 of postnatal life with either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 8). 
dType I error probability for the effect of leptin antagonist.  NS = P>0.15. 
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Figure  5.7  Effect of leptin antagonist therapy on voluntary dry matter intake in late 
postnatal life. 
Lambs were treated between day 30 and 35 of postnatal life with either excipient 
(Control, n = 6) or leptin antagonist (SOLA, n = 8).  Treatment and post-treatment 
periods were analyzed separately. The P-values are given only for effects that were 
significant (P<0.05) or tended to be significant (P<0.15). The pooled SE were 26.7 for n 
= 8 and 30.9 for n = 6 during the treatment period, and 34.4 for n = 8 and 40.3 for n = 6 
during the post-treatment period. 
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Figure  5.8  Effect of leptin antagonist therapy on relative dry matter intake in late 
postnatal life. 
Lambs were treated between day 30 and 35 of postnatal life with either excipient 
(Control, n = 6) or leptin antagonist (SOLA, n = 8).  Treatment and post-treatment 
periods were analyzed separately. The P-values are given only for effects that were 
significant (P<0.05) or tended to be significant (P<0.15).  The pooled SE were 1.9 for n = 
8 and 2.2 for n = 6 during the treatment period, and 2.0 for n = 8 and 2.3 for n = 6 during 
the post-treatment period. 
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Figure  5.9  Effect of leptin antagonist therapy on fractional weight gain in late 
postnatal life. 
Lambs were treated between day 30 and day 35 of postnatal life with either excipient 
(Control, n = 6) or leptin antagonist (SOLA, n = 8). Treatment and post-treatment periods 
were analyzed separately. The P-values are given only for effects that were significant 
(P<0.05) or tended to be significant (P<0.15). The pooled SE were 0.4 for n = 8 and 0.5 
for n = 6 during the treatment period, and 0.6 for n = 8 and 0.7 for n = 6 during the post-
treatment period. 
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Figure  5.10  Effect of leptin antagonist therapy on body weight in late postnatal life. 
Lambs were treated between day 30 and day 35 of postnatal life with either excipient 
(Control, n = 6) or leptin antagonist (SOLA, n = 8).  Treatment and post-treatment 
periods were analyzed separately. The P-values are given only for effects that were 
significant (P<0.05) or tended to be significant (P<0.15).  The pooled SE was 0.2 during 
the treatment period and 0.3 during the post-treatment period for both groups. 
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analyzed as an overall average (Table 5.7, SOLA, P<0.05) or over time (Fig. 5.9, post-
treatment, SOLA P<0.01). 
Plasma variables.  Plasma SOLA progressively increased linearly over the first 3 
days of treatment and plateaued to 1543 ng/ml over the last 3 day of treatment (Fig. 
5.11).  The plasma leptin concentration over the same period averaged 5 ng/ml in the 
Control animals (Fig. 5.11).  Accordingly, plasma SOLA concentration was ~309-fold 
higher than endogenous leptin over the last 3 days of treatment (Fig. 5.11).  The plasma 
SOLA concentration dropped to 423 and 87 ng/ml by 56 and 112 h after the last injection.  
Plasma concentrations of glucose and various metabolic hormones were similar before 
treatment (day 28 and 29 of age), with the exception of plasma T4, which tended to be 
higher in the SOLA group (Control vs. SOLA, 135 vs. 156 nmol/l, P<0.10).  During 
treatment, SOLA had no effect on the profile of plasma concentration of glucose and 
insulin over time (results not shown) or on the average concentrations during the 
treatment period (Table 5.8).  In contrast SOLA caused a progressive reduction in 
plasma T4 over the first 3 days of treatment followed by a maximal reduction over the 
last 3 days (Fig. 5.12, SOLA x Day, P<0.007). 
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Table  5.7 Effect of leptin antagonist therapy on intake and growth during the posttreatment period (day 36 to 39 of postnatal 
life). 
 Treatmentc  
Probability leveld Variablea  Control SOLA SD 
Dry matter intake     
Absoluteb, g/d 482 433 82 NS 
Relative to LW, g/kg  d 33 29 4 0.11 
Energy intake     
Absoluteb, kcal/d 2826.4 2540.2 478.8 NS 
Relative to LW, kcal/kg  d 193.0 170.2 24.7 0.11 
Relative to MBW, kcal/kg0.58 d 571.6 545.6 82.5 NS 
Growth     
Weight on day 36 kg 14.35 14.48 0.66 NS 
Weight gainb, kg 1.35 0.99 0.56 NS 
Weight on day 39b, kg 15.71 15.48 0.95 NS 
ADGb, kg/day 0.33 0.27 0.14 NS 
FWG, %/day 2.8 2.0 0.6 <0.05 
aLW, live weight; MBW, metabolic body weight (kg0.58); ADG, average daily gain; FWG, fractional weight gain. 
bAdjusted by covariate analysis for pre-treatment body weight. 
c Lambs were treated from day 30 to 35 of postnatal life with either excipient (Control, n = 6) or leptin antagonist (SOLA, n = 8). 
dType I error probability for the effect of leptin antagonist.  NS = P>0.15. 
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Figure  5.11  Concentration of endogenous plasma leptin or leptin antagonist 
during treatment. 
Lambs were treated between day 30 and 35 of postnatal life with either excipient 
(Control, n=6) or leptin antagonist (SOLA, n=8).  Blood samples were obtained in the 
indicated days at 1600 h, 8 hours after the first daily IV injection.  Arrow indicates the last 
day of treatment.  Plasma SOLA was measured only in SOLA-treated lambs (top panel), 
and endogenous plasma leptin was measured only in control animals (bottom panel).  
The pooled SE was 247 for SOLA and 0.5 for leptin. 
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Table  5.8  Effect of late leptin antagonist therapy on the plasma concentration of 
glucose and selected hormones during treatment period (day 30 to 35 of postnatal 
life). 
 Treatmenta  Probability 
levelb Variable Control SOLA SD 
Insulin, ng/ml 3.7 5.3 1.8 NS 
Glucose, mg/dl  110 105 6 NS 
Leptin, ng/ml 5.0 --- 0.2 --- 
SOLA, ng/ml  --- 1252 371 --- 
bLambs were treated between day 30 and day 35 of postnatal life with either excipient 
(Control, n=6) or leptin antagonist (SOLA, n=8). 
cType I error probability.  NS = P>0.15. 
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Lambs were treated between day 30 and 35 of postnatal life with either excipient 
(Control, n = 6) or leptin antagonist (SOLA, n = 8).  For each day of treatment, the 
change in plasma T4 concentration (Δ plasma T4) was calculated as the difference from 
pre-treatment plasma T4 (average of day 28 and 29 of age).  The P-values are given 
only for effects that were significant (P<0.05) or tended to be significant (P<0.15).  The 
pooled SE were 4.6 for n = 8 and 5.3 for n = 6.  
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Figure  5.12  Effect of late leptin antagonist therapy on plasma delta T4 in late 
postnatal life. 
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Discussion 
Leptin is known to induce hypothalamic signaling in mice during the first 16 days 
of life without changes in body weight or body fat content (15, 16).  This is thought to 
reflect the immature state of axonal connections between the ARC and the more distal 
hypothalamic nuclei responsible for intake regulation (13, 15).  Nevertheless, neonatal 
leptin is crucial because it acts as a neurotrophic factor driving the extension of ARC-
derived axons towards their distal targets.  In rodents, leptin appears to play this role 
within a small developmental window.  First, rodents experience a spike in plasma leptin 
during the first two weeks of life (30).  It is during this time window that leptin treatment 
efficiently promotes the growth of hypothalamic axonal projections in ob/ob mice (13).  
Interestingly, disruption of leptin concentration or its signaling during early life appears to 
be the mechanism whereby many fetal nutritional insults lead to an enhanced appetite 
and excessive fat deposition in postnatal life (5, 12, 31).  For example, maternal 
undernutrition during gestation abolishes the leptin early postnatal spike in IUGR pups 
and appears to disrupt the normal development of the hypothalamic network responsible 
for energy homeostasis (12).  In contrast, early leptin therapy of IUGR rat pups is 
sufficient to correct later disruption of energy metabolism including excessive appetite 
and obesity in later life (5).  Whether leptin plays a similar sole in humans and other 
precocial animals remains largely undefined.  The sheep is considered an appropriate 
model because the ontogeny of hypothalamic development is thought to approximate 
that of primates, including humans (17–19).   
Studies of leptin action in the sheep have been limited to juvenile or adult 
animals.  It has been demonstrated that intracerebroventricular infusion of leptin can 
reduce voluntary intake, increase muscle thermogenesis and GH secretion in well-fed 
animals, as well as normalize LH secretion in long-term food restricted ewes (32–34).  
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Remarkably, peripheral infusion of exogenous leptin is ineffective in affecting intake or 
endocrine changes in well-fed sheep (35) but is effective in correcting LH pulses of 
underfed ewes only when they are ovarectomized (36).  This might indicate that in 
normal precocial animals, like sheep, leptin therapy is effective only when leptin is 
abnormally low.  Accordingly, as a first step to assess a functional role of leptin in 
neonatal sheep, we opted for a strategy that would reduce naturally occurring leptin 
signaling.  
Gertler et al. (37) initiated the development and evaluation of leptin antagonists.   
The first generation of leptin antagonists was based on the mutagenesis of amino acid 
residues 39 to 41 with alanine (L39A/D40A/F41A).  This leptin mutant has the same 
affinity for the receptor as wild-type leptin but has no signaling activity (37).  The second 
generation of leptin-antagonist incorporated the additional substitution of aspartic acid 
residue 23 by a non-charged amino-acid (D23L), leading to an 8-fold increase in binding 
affinity for the leptin receptor (22).  Finally, a polyethylene glycol molecule was attached 
to the molecule (20).  Pegylation reduced renal clearance of leptin and induced 16-fold 
increase in half-life compared to wild-type leptin (20), thereby, increasing substantially 
the biological antagonistic activity of SOLA.  Studies performed in the mouse with the 
pegylated mouse version showed that its predominant mode of action was competitive 
inhibition of blood to brain leptin transport (20).  Shpilman et al. (21) administered the 
mouse version of this antagonist by SC injection to growing mice and used body weight 
change as an end point.  The mouse version antagonist was maximally effective at the 
dose of 6.7 mg/kg/d (43% greater weight change compared to controls) and 70% as 
effective at the dose of 2.2 mg/kg/d (21).  The equivalent 70% effective dose on a 
metabolic BW basis for a newborn lamb is 0.91 mg/kg0.75.  Because we delivered this 
leptin antagonist via intravenous injection, we settled for a daily dose of 0.46 mg/kg0.75 
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during the early period of administration.  This resulted in a 237-fold excess of SOLA vs. 
wild-type leptin.  We chose to double this dose during the late SOLA treatment to 
counteract the natural rise in endogenous leptin production and achieved a 309-fold 
excess. 
We chose to treat lambs at two distinct times during early postnatal life.  In or 
initial study, we treated lambs for the first 14 days of postnatal life given the observation 
that leptin promotes hypothalamic axonal growth immediately after birth in rodents and 
that such an effect could have long-term impact on energy metabolism (13, 15).  SOLA 
treatment did not statistically increase dry matter intake over this period.  The profile of 
dry matter intake over time was nevertheless suggestive of leptin regulation.  SOLA-
treated lambs had a numerical increase in feed intake for the entire 14-day treatment 
and this effect was lost upon cessation of treatment.  This was somewhat surprising 
given the notion that gut limitation is a primary regulator of food intake in immediate 
postnatal life (Chapter 3).  Moreover, SOLA treatment was associated with a significant 
increase of growth that was lost as soon as treatment was discontinued (Fig. 3).  
Abdennebi-Najar et al. (38) demonstrated that hypothalamic leptin signaling cascade 
was blocked after 45 min of a single IV injection of the rat version of this leptin 
antagonist in 1-day old pups.  Moreover, Benoit et al. (39) evaluated the effect of leptin 
antagonist treatment in rat pups from postnatal day 2 to 13.  In contrast to our 
observations in lambs, early leptin antagonist treatment induced long-term hyperphagia 
measured at P90 under regular chow regime and at P150 when challenged with a high 
fat diet (39).  This hyperphagia was associated with higher rates of weight gain through 
adulthood on day 153 (39).  The temporality of effects and the lack of differences in body 
composition at day 40 of life suggest that leptin signaling during early life in precocial 
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species does not have the same relevance and long lasting consequences than it does 
in rodents. 
A previous experiment conducted in our lab demonstrated that newborn lambs 
during the first two weeks of life are incapable of reducing voluntary intake when caloric 
density of the diet is increased (Chapter 3).  This suggested that dry matter intake in 
early life may be limited by physical constraints rather than by a central system 
responding to metabolic cues.  Thereafter, we treated lambs between day 30 and 35 
when GI tract capacity is presumably no longer limiting intake.  To our surprise, chronic 
SOLA treatment did not increase voluntary intake during this later treatment period.  
However, weight gain was higher in SOLA-treated lambs during the same period.  
Similar observations were made in mice.  Chronic treatment with pegylated mouse leptin 
antagonist for 8 days numerically increased food intake and significantly increased body 
weight (20). Interestingly, lambs treated with SOLA had a significant reduction in relative 
dry matter intake and a numerical reduction in weight gain relative to Control group 
during the post-treatment period.  As suggested by Elinav et al. (20), this effect after 
chronic leptin antagonist treatment could be the result of a compensatory state of 
enhanced leptin sensitivity.  It is possible that a longer treatment period with the leptin 
antagonist could induce an effect on dry matter intake.  It is noteworthy that the leptin 
antagonist treatment reduced circulating T4 only when administered on day 30 and not 
during the immediate postnatal period.  Previously, we demonstrated that plasma T4 
concentration responds to changes in caloric content of the diet only after 7 to10 days 
after birth (Chapter 3).  It is possible that there is a refractory period immediately after 
birth when the central regulation of circulating T4 does not operate.  This would explain 
the lack of effect of SOLA on plasma T4 immediately after birth.  
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Previously, Levi et al. (40) demonstrated that glucose metabolism in 7-wk old 
mice can be altered by treatment with pegylated leptin for 3 days.  Although fasting 
glucose and glucose tolerance were not different in treated animals, they showed higher 
fasting-insulin and glucose-dependent insulin secretion.  Also, during hyperinsulinemic-
euglycemic clamps, hepatic glucose output was suppressed 90% in control mice but 
only 39% in mice treated with the leptin antagonist (40).  Although we were not able to 
detect differences in plasma insulin or glucose between groups, it is difficult to draw any 
conclusions because blood samples were not obtained under fasting conditions.  On the 
other hand, it is well known that leptin can alter metabolic rate by increasing thyroid 
hormones concentration (41, 42).  Upon leptin stimulation, neurons in the arcuate 
nucleus (ARC) increase the synthesis and secretion of thyrotropin-releasing hormone 
(41).  This process takes place through the stimulation of melanocortin receptors in 
second order neurons distal from the ARC.  For example, Rosenbaum et al. (42) 
demonstrated that exogenous leptin can increase circulating thyroid hormones levels in 
humans with low plasma leptin levels during sustained weight reductions of 10%.  More 
importantly, such leptin treatment increased energy expenditure and further reduced fat 
mass (42). Accordingly, in our experiment, blockage of leptin signaling induced a 
significant decrease in plasma total T4 concentration when lambs were treated at day 30 
of post-natal life.  It is known that circulating thyroid hormones are associated with 
metabolic rate and energy expenditure (43).  Therefore, the effects of leptin antagonist 
on T4 could explain the slightly higher rate of weight gain of treated lambs (Fig. 10) 
without significant changes in intake during the late treatment period.   
In summary, our study suggests that leptin is functional after birth in sheep and 
can regulate food intake.  Although, leptin antagonist appeared to increase voluntary 
intake and growth during the first two weeks of life, these effects were transient and did 
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not have long-lasting effects on body composition at 40 days of postnatal life.  
Interestingly, the effect of leptin on thyroid function was not observed during this period 
but was evident when animals were treated later in life.  This is likely the consequence of 
a refractory period in the central regulation of thyroid hormones in early life.  In 
conclusion, leptin signaling during the first two weeks of life does not have the same 
implications in lambs as it does in rodents.  Also, the role of leptin on the ontogeny of 
hypothalamic development remains to be investigated.  Due to the altricial nature of 
sheep, fetal life could offer a better window to explore this developmental process. 
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CHAPTER  6 :   SUMMARY AND CONCLUSIONS 
It has been discovered that the abnormal appetite and obesity of IUGR rodents is 
associated with defective hypothalamic centers regulating energy metabolism (1).  In 
parallel, it was discovered that rodents develop a leptin surge that is not related to 
adiposity or appetite regulation during the first two weeks of life (2).  During this period, 
leptin has essential neurotrophic effects in the hypothalamus, promoting axonal 
connections between neuronal centers responsible for energy homeostasis (3).  The 
neonatal leptin peak is disrupted as a result of IUGR or other perinatal insults in rodents.  
This phenomenon induces a permanent disruption in the central control of energy 
homeostasis and a detrimental adult phenotype.   
Although rodent models have been informative in exploring the postnatal 
consequences of the IUGR conditions and the mechanisms involved, the timing of final 
maturation of the hypothalamus differs between altricial rodents and precocial species 
like humans.  For example, most of the hypothalamic development observed in rodents 
during neonatal life is believed to take place prenatally in precocial species (4–6).  
Additionally, rodent models offer experimental difficulties to study the effects of dietary 
caloric density on energy homeostasis during the pre-weaning period.  Sheep models 
are an alternative to overcome these limitations.  The ontogenesis of energy 
homeostasis in the sheep is believed to be similar to humans (7).  Also, they can be 
artificially reared using milk replacer of different composition.  Because of these 
advantages, we conducted studies using an IUGR sheep model to evaluate the role of 
dietary fat during early life.  We also evaluated the role of the leptin-MC system in the 
control of energy homeostasis during neonatal life 
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Our first experiment investigated the interactions between birth size and fat 
content of the diet during the first 2 weeks of life of neonatal lambs (Chapter 3). Dietary 
fat content did not change dry matter intake of IUGR or Normal lambs during the first two 
weeks of life, suggesting that capacity of the GI tract is a primary factor limiting energy 
intake.  By the second week of life, however, voluntary feed intake in animals receiving 
the HFD developed a curvilinear pattern whereas the pattern remained linear in animals 
fed a low-fat milk replacer.  These data suggest that the homeostatic system regulating 
energy metabolism may become operational after the first week of life.  Our data do not 
suggest that IUGR lambs differ from Normal lambs with respect to either mechanism 
(physical limitation or central regulation of feed intake).  In agreement with results of 
others in sheep and rodent models, the IUGR condition favored greater lipid deposition.  
This effect was most obvious for the visceral fat depots.  This effect suggests that the 
IUGR sheep model is very relevant to human health.  Indeed, evidence in humans 
indicates that the IUGR condition is associated with higher visceral fatness in adulthood 
(8).  Additionally the association between the IUGR condition, hypothyroid status and 
greater fat accretion indicate that lower metabolic rate might play an important role in the 
development of excess adiposity in these animals.   
In future experiments, it will be important to determine whether IUGR and normal 
lambs differ in the development of hypothalamic networks during prenatal and postnatal 
life.  Such data would provide information about the ontogeny of central control of energy 
homeostasis and effects of the IUGR condition.  It will also be important to use 
experimental techniques to assess effects of the IUGR condition on energy expenditure.  
Indirect calorimetry, thermologgers and determination of respiratory exchange ratio 
could provide this type of information (9, 10).  Experiments with IUGR lambs would also 
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benefit from the accurate and repeatable in vivo measurement of body composition to 
assess long-term effect of this condition. 
The central MC system plays a critical role in regulating voluntary food intake and 
energy expenditure (11).  In fact, its activation is one of the most important mechanisms 
whereby leptin regulates energy metabolism in postnatal life (12).  Whether this system 
operates in early postnatal life was unknown.  Our second experiment demonstrated that 
melanocortin receptor-4 signaling is functional in IUGR lambs as early as 4 days of life.  
Also we demonstrated that melanocortin activation could be an effective method to 
reduce relative intake and fatness associated with the IUGR condition, but the outset, we 
planned to have an additional experimental group of pair-fed IUGR lambs to determine 
whether melanocortin agonist treatment had effects above and beyond any intake 
effects.  A lack of IUGR lambs prevented this.  Nevertheless multivariate analysis 
suggested effects of the melanocortin agonist on fat deposition involving intake-
independent effects.  It was clear that these effects were associated with an increase in 
circulating T4 and lower fat retention in treated animals.  Additional experiments are 
needed to ascertain this possibility.  Moreover, it would be interesting to assess whether 
IUGR and Normal lambs have similar sensitivity and responsiveness to MC stimulation. 
The neurotrophic effect of leptin in neonatal rodents has received lots of attention 
(3).  In particular, disruption this effect has been regarded as a likely mechanism 
explaining the predisposition of obesity in IUGR animals, including humans (13).  The 
timing of leptin action after birth in precocial species, including humans, however, 
remains unknown.  In our final experiment, we explored the importance of leptin 
signaling in energy homeostasis during early life using a long-lasting leptin antagonist for 
two weeks after birth.  This experiment also allowed us to examine the long-term 
consequences of disrupted leptin signaling during this period, a known sensitive 
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developmental window in rodents (3).  The leptin antagonist numerically increased 
intake of newborn lambs but this effect disappeared at cessation of treatment.  Although, 
the number of experimental units in our experiment was not sufficient to reach 
significance, these observations strongly suggest that leptin has a role in the regulation 
of voluntary intake during the immediate postnatal period.  This is supported by a 
significant increase in growth rate of lambs treated with leptin antagonist exclusively 
during the treatment period.  Additionally, this experiment demonstrated that disruption 
of leptin signaling during the first 14 days of life did not have carry-over effects on intake, 
growth or body composition up to day 40 of life.  Therefore, variation in postnatal leptin 
signals immediately after birth does not seem to be as critical in precocial animals as it is 
in rodents.  Based on the findings of our first experiment, we decided to analyze the 
effect of leptin antagonist treatment at an age when the GI tract would presumably no 
longer impose a limitation to intake.  We tested the effect of a 5-day treatment starting at 
postnatal day 30.  Although no differences in intake were detected, leptin antagonist 
decreased T4 concentration in treated lambs, presumably reducing metabolic rate.  It is 
possible that a longer treatment period is necessary to induce a change in intake.  Also, 
in the future, it is necessary to assess different and additional responses to leptin 
signaling disruption.  For example: changes in hypothalamic networks, changes in body 
composition and their association with energy intake and expenditure as well as dynamic 
assessment of glucose metabolism particularly at the onset and termination at treatment.  
Overall, these experiments provide new information on the regulation of energy intake 
immediately after birth in an animal model that approximates the timing of hypothalamic 
development in humans. 
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